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Obstetricians and Gynecologists, and the American College o f Nurse-Midwives. 
ACIP recommendations adopted by the C D C  Director become agency guidelines 
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M e n i n g o c o c c a l  d i s e a s e  d e s c r i b e s  t h e  s p e c t r u m  o f  i n f e c t i o n s  c a u s e d  b y  Neisseria meningiditis, i n c l u d i n g  m e n i n g i t d i s ,  b a c t e r e m i a ,  
a n d  b a c t e r e m i c  p n e u m o n i a .  T w o  q u a d r i v a l e n t  m e n i n g o c o c c a l  p o l y s a c c h a r i d e - p r o t e i n  c o n j u g a t e  v a c c i n e s  t h a t  p r o v i d e  p r o t e c t i o n  
a g a i n s t  m e n i n g o c o c c a l s e r o g r o u p s  A ,  C ,  W ,  a n d  Y ( M e n A C W Y - D  [ M e n a c t r a ,  m a n u f a c t u r e d  b y  S a n o f i  P a s t e u r ,  I n c . ,  S w i f t w a t e r ,  
P e n n s y l v a n i a ]  a n d  M e n A C W Y - C R M  [ M e n v e o ,  m a n u f a c t u r e d  b y  N o v a r t i s  V a c c i n e s ,  C a m b r i d g e ,  M a s s a c h u s e t t s ] )  a r e  l i c e n s e d  
i n  t h e  U n i t e d  S t a t e s  f o r  u s e  a m o n g  p e r s o n s  a g e d  2 t h r o u g h  55 y e a r s .  M e n A C W Y - D  a l s o  i s  l i c e n s e d  f o r  u s e  a m o n g  i n f a n t s  a n d  
t o d d l e r s  a g e d 9  t h r o u g h  23 m o n t h s .  Q u a d r i v a l e n t  m e n i n g o c o c c a l  p o l y s a c c h a r i d e  v a c c i n e  ( M P S V 4  [ M e n o m m u n e ,  m a n u f a c t u r e d  
b y  s a n o f i  p a s t e u r ,  I n c . ,  S w i f t w a t e r ,  P e n n s y l v a n i a ] )  i s  t h e  o n l y  v a c c i n e  l i c e n s e d  f o r  u s e  a m o n g  p e r s o n s  a g e d  >56 y e a r s .  A  b i v a l e n t  
m e n i n g o c o c c a l  p o l y s a c c h a r i d e  p r o t e i n  c o n j u g a t e  v a c c i n e  t h a t  p r o v i d e s  p r o t e c t i o n  a g a i n s t  m e n i n g o c o c c a l  s e r o g r o u p s  C  a n d  Y  a l o n g  
w i t h  Haemophilus influenzae t y p e  b  ( H i b )  ( H i b - M e n C Y - T T  [ M e n H i b r i x ,  m a n u f a c t u r e d  b y  G l a x o S m i t h K l i n e  B i o l o g i c a l s ,  
R i x e n s a r t ,  B e l g i u m ] )  i s  l i c e n s e d  f o r  u s e  i n  c h i l d r e n  a g e d  6  w e e k s  t h r o u g h  18 m o n t h s .
T h i s  r e p o r t  c o m p i l e s  a n d  s u m m a r i z e s  a l l  r e c o m m e n d a t i o n s  f r o m  C D C ’s  A d v i s o r y  C o m m i t t e e  o n  I m m u n i z a t i o n  P r a c t i c e s  ( A C I P )  
r e g a r d i n g  p r e v e n t i o n  a n d  c o n t r o l  o f  m e n i n g o c o c c a l  d i s e a s e  i n  t h e  U n i t e d  S t a t e s ,  s p e c i f i c a l l y  t h e  c h a n g e s  i n  t h e  r e c o m m e n d a t i o n s  
p u b l i s h e d  s i n c e  2005 ( C D C .  P r e v e n t i o n  a n d  c o n t r o l  o f  m e n i n g o c o c c a l  d i s e a s e :  r e c o m m e n d a t i o n s  o f  t h e  A d v i s o r y  C o m m i t t e e  
o n  I m m u n i z a t i o n  P r a c t i c e s  [ A C I P ] .  M M W R  2005; 54[ N o .  R R - 7] ) .  A s  a  c o m p r e h e n s i v e  s u m m a r y  o f  p r e v i o u s l y  p u b l i s h e d  
r e c o m m e n d a t i o n s ,  t h i s  r e p o r t  d o e s  n o t  c o n t a i n  a n y  n e w  r e c o m m e n d a t i o n s ;  i t  i s  i n t e n d e d  f o r  u s e  b y  c l i n i c i a n s  a s  a  r e s o u r c e .  A C I P  
r e c o m m e n d s  r o u t i n e  v a c c i n a t i o n  w i t h  a  q u a d r i v a l e n t  m e n i n g o c o c c a l  c o n j u g a t e  v a c c i n e  ( M e n A C W Y )  f o r  a d o l e s c e n t s  a g e d  11 o r  12 
y e a r s ,  w i t h  a  b o o s t e r  d o s e  a t  a g e  16 y e a r s .  A C I P  a l s o  r e c o m m e n d s  r o u t i n e  v a c c i n a t i o n  f o r  p e r s o n s  a t  i n c r e a s e d  r i s k  f o r  m e n i n g o c o c c a l  
d i s e a s e  ( i . e . ,  p e r s o n s  w h o  h a v e  p e r s i s t e n t  c o m p l e m e n t  c o m p o n e n t  d e f i c i e n c i e s ,  p e r s o n s  w h o  h a v e  a n a t o m i c  o r  f u n c t i o n a l  a s p l e n i a ,  
m i c r o b i o l o g i s t s  w h o  r o u t i n e l y  a r e  e x p o s e d  t o  i s o l a t e s  o f  N. meningitidis, m i l i t a r y  r e c r u i t s ,  a n d  p e r s o n s  w h o  t r a v e l  t o  o r  r e s i d e  
i n  a r e a s  i n  w h i c h  m e n i n g o c o c c a l  d i s e a s e  i s  h y p e r e n d e m i c  o r  e p i d e m i c ) .  G u i d e l i n e s  f o r  a n t i m i c r o b i a l  c h e m o p r o p h y l a x i s  a n d  f o r  
e v a l u a t i o n  a n d  m a n a g e m e n t  o f  s u s p e c t e d  o u t b r e a k s  o f  m e n i n g o c o c c a l  d i s e a s e  a l s o  a r e  p r o v i d e d .
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I n t r o d u c t i o n
This report compiles and summarizes all recommendations from 
CDC’s Advisory Committee on Immunization Practices (ACIP) 
regarding prevention and control of meningococcal disease in the 
United States, specifically the changes in the recommendations 
published since 2005 (1 ), and describes the process undertaken 
and the rationale used in support of these recommendations.
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This report is a comprehensive summary of previously published 
recommendations (Box 1) and does not contain any new 
recommendations; it is intended for use by clinicians as a resource. 
Guidelines for antimicrobial chemoprophylaxis (Appendix A) and 
evaluation and management ofsuspected outbreaks ofmeningococcal 
disease (Appendix B) also are provided.
Meningococcal disease describes the spectrum of infections 
caused by N e i s s e r i a  m e n i n g i t i d i s , including meningitis, 
bacteremia, and bacteremic pneumonia. Meningococcal disease 
develops rapidly, typically among previously healthy children 
and adolescents, and results in high morbidity and mortality. 
For unknown reasons, incidence has declined since the peak 
of disease in the late 1990s, and approximately 800—1,200 
cases are reported annually in the United States. This decline 
began before implementation of routine use of meningococcal 
vaccines in adolescents and have occurred in all serogroups. 
Four vaccines are licensed in the United States and provide 
protection against four (A, C , W, and Y) and two (C and Y) 
serogroups (Table 1 ). Vaccines that protect against serogroup 
B meningococcal disease are not available in the United States.
Meningococcal vaccination is recommended for groups at 
increased risk for disease. These groups include adolescents, 
persons with certain medical conditions, and persons with 
increased risk for exposure. Among these risk groups, the 
number of vaccine doses (i.e., 2- or 4-dose primary series or a 
single dose with or without a booster dose) and vaccine product 
are determined by the indication for vaccination and age. In 
certain situations such as special dosing regimens (i.e., booster 
dose[s] or serial vaccination and 2-dose primary series for 
persons aged >2 years), off-label use of meningococcal vaccine 
has been recommended. Special dosing regimens have been 
recommended on the basis of data from studies of immunologic 
response to vaccination, postlicensure observational data, and 
the need for long-term protection in certain risk groups ( 2— 4) .
ACIP recommendations for meningococcal vaccination have 
been summarized (Box 2). Details regarding dosing (2- or 4-dose 
primary series or a single dose with or without a booster dose), 
contraindications, precautions, and special circumstances (e.g., 
adolescents infected with human immunodeficiency virus [HIV] 
and asplenic children) are described elsewhere in this report (see 
Recommendations for Use of Meningococcal Vaccines).
M e t h o d s
A CIP’s Meningococcal Vaccines Work Group* (the Work 
Group) revised the meningococcal vaccine recommendations 
on the basis of the most current data on safety, efficacy, and 
immunogenicity of meningococcal vaccines. The Work Group
* A list of the Work Group appears on Page 28.
BOX 1. T im eline o f m eningococcal con jugate  vaccine ACIP 
recommendations, 2005 —  2012
2005: Licensure of and first recommendation for routine 
vaccination of adolescents with MenACWY-D.*
2006: Because of limited vaccine supply, vaccination was 
first limited to cohorts of children entering high school and 
entering college and persons aged 11—55 years at increased 
risk for meningococcal disease.̂
2007: After vaccine supply became sufficient, ACIP 
recommended vaccination for all adolescents aged 11—18 
years.§ ACIP recommended vaccination of children aged 2—10 
years at increased risk for meningococcal disease.̂
2009: ACIP recommended booster dose for persons 
who remain at increased risk for meningococcal disease, 
administered every 5 years except for children who received 
their previous dose prior to their seventh birthday; these 
children should receive a booster dose 3 years after their 
previous dose.**
2010: The Food and Drug Administration licensed a 
second vaccine product, MenACWY-CRM.tt ACIP added 
a booster dose at age 16 years and recommended a 2-dose 
primary series for all persons with asplenia, persistent 
complement component deficiency, and for persons with 
human immunodeficiency virus infection.§§
2011: ACIP recommended a 2-dose primary series 
for children aged 9—23 months at increased risk for 
meningococcal disease.^
2012: ACIP recommended a 4-dose primary series of Hib- 
MenCY-TT for children aged 2—18 months at increased risk 
for meningococcal disease.***
* Source: C D C  Prevention and control o f meningococcal disease:
recommendations o f the Advisory Committee on Immunization 
Practices (ACIP). M M W R 2005;54(No. RR-7).
 ̂Source: CDC. Notice to readers: limited supply of meningococcal 
conjugate vaccine, recommendation to defer vaccination of persons 
aged 11-12 years. M M W R 2006:55;567-8.
§ Source: CDC. Revised recommendations of the Advisory Committee on 
Immunization Practices to vaccinate all persons aged 11-18 years with 
meningococcal conjugate vaccine. M M W R 2007;56:794-5.
J Source: CDC. Recommendation from the Advisory Committee on 
Immunization Practices (ACIP) for use of quadrivalent meningococcal 
conjugate vaccine (MCV4) in children aged 2-10 years at increased risk 
for invasive meningococcal disease. MMWR 2007;56:1265-6.
** Source: CDC. Updated recommendation from the Advisory Committee 
on Immunization Practices (ACIP) for revaccination of persons at 
prolonged increased risk for meningococcal disease. M M W R
2009;58:1042-3.
^  Source: CDC. Licensure of a meningococcal conjugate vaccine 
(M enveo) and guidance for use— A dvisory C o m m ittee  on 
Immunization Practices (ACIP), 2010. M M W R 2010;59:273.
§§ Source: CDC. Updated recommendations for use o f meningococcal 
conjugate vaccines—Advisory Committee on Immunization Practices 
(ACIP), 2010. M M W R 2011;60:72-6.
Source: CDC. Recommendation o f the Advisory Committee on 
Immunization Practices (ACIP) for use of quadrivalent meningococcal 
conjugate vaccine (MenACWY-D) among children aged 9 through 
23 months at increased risk for invasive meningococcal disease. 
M M W R 2011;60:1391-2.
*** Source: CDC. Infant meningococcal vaccination: Advisory Committee 
on Immunization Practices (ACIP) recommendations and rationale. 
M M W R 2013;62:52-4.
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TABLE 1. Licensed meningococcal vaccines —  United States, 1981-2012
Formulation Type Trade name Manufacturer Licensed (yr) Age group Dose(s) Serogroups
MPSV4* Polysaccharide Menomune Sanofi Pasteur 1981 >2 yrs Single dose A, C, W, and Y
MenACWY-D1 Conjugate Menactra Sanofi Pasteur 2005 11-55 yrs Single dose A, C, W, and Y
MenACWY-D1 Conjugate Menactra Sanofi Pasteur 2007 2-10 yrs Single dose A, C, W, and Y
MenACWY-D1" Conjugate Menactra Sanofi Pasteur 2011 9-23 mos 2-dose series A, C, W, and Y
MenACWY-CRM§ Conjugate Menveo Novartis 2010 11-55 yrs Single dose A, C, W, and Y
MenACWY-CRM§ Conjugate Menveo Novartis 2011 2-10 yrs Single dose A, C, W, and Y
Hib-MenCY-TU Conjugate MenHibrix GlaxoSmithKline 2012 6 wks-18 mos 4-dose series C and Y
* Package insert available at http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM308370.pdf. 
f Package insert available at http://www.fda.gov/downloads/BiologicBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf.
§ Package insert available at http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf. 
11 Package insert available at http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM308577.pdf.
comprises a diverse group of health-care providers and public 
health officials, including professionals from academic medicine 
(pediatrics, family practice, internal medicine, and infectious 
disease specialists), federal and state public health professionals, 
and representatives of provider organizations. Since 2006, the 
Work Group has held teleconference meetings monthly and has 
held in-person meetings once or twice a year to discuss recently 
published studies, review current guidelines, and consider potential 
revisions to the recommendations. During these meetings, CDC 
staff members, pharmaceutical manufacturer representatives, 
and other academic partners delivered presentations on 
meningococcal disease epidemiology, immunogenicity and safety 
of meningococcal vaccines, cost effectiveness, programmatic 
considerations, and vaccine effectiveness studies.
The Work Group considers published, peer-reviewed studies as 
the primary source of data in making recommendations for the 
prevention and control of meningococcal disease. In addition, 
unpublished data (e.g., immunogenicity and safety data in age 
groups outside the licensed indication) that are relevant to issues 
under discussion also were considered. Randomized, controlled 
clinical trials for meningococcal vaccines are unable to evaluate 
clinical efficacy because of the low incidence of meningococcal 
disease; because efficacy cannot be measured, immunogenicity 
data are used as a surrogate for efficacy for licensure.
In addition, because rare adverse events might not be observed 
in prelicensure clinical trials because of the limited number of 
subjects enrolled, postlicensure observational data also were used 
in the assessment of meningococcal vaccines. Observational data 
included reports of vaccine failures, a postlicensure case-control 
study, Vaccine Adverse Events Reporting System (VAERS) data 
(12), and safety data collected from the Vaccine Safety Datalink 
(VSD) (13). Data reviewed on the incidence and burden of 
disease came from the Active Bacterial Core surveillance (ABCs) 
system and the National Notifiable Diseases Surveillance 
System (NNDSS) (14). The evidence for the benefits and 
risks of meningococcal vaccination in infants and toddlers was 
evaluated using the Grading of Recommendations, Assessment, 
Development, and Evaluation (GRADE) framework (GRADE
evidence tables for toddler and infant meningococcal vaccine 
are available at http://www.cdc.gov/vaccines/acip/recs/GRADE/ 
mening-vac-infants.html).
Summaries of the data reviewed and Work Group discussions 
were presented to ACIP before changes were proposed to the 
recommendations. Proposed changes to meningococcal vaccine 
recommendations were presented at nine ACIP meetings from 
October 2007 through October 2012. During these nine 
meetings, recommendations were approved either as submitted 
or as amended and approved by ACIP, and ACIP members 
approved a draft of this report in April 2012. During the review 
process, CD C modified the statement to update and clarify 
wording in the report.
BOX 2. Meningococcal vaccination recommendations —  Advistory 
Committee on Immunization Practices, 2013
ACIP recommends meningococcal vaccination for the 
following groups:
• Routine vaccination of adolescents aged 11 through 18 years 
(a single dose of vaccine should be administered at age 1 1  or 
12 years, with a booster dose at age 16 years for persons who 
receive the first dose before age 16 years) (1,5—7).
• Routine vaccination of persons aged >2 months at increased 
risk for meningococcal disease, including (7—11):
— Persons aged >2 months with certain medical conditions 
such as anatomical or functional asplenia or complement 
component deficiency (dosing schedule and interval for 
booster dose varies by age at time ofprevious vaccination).
— Special populations such as unvaccinated or incompletely 
vaccinated first-year college students living in residence 
halls, military recruits, or microbiologists with 
occupational exposure (indication for booster dose 5 
years after prior dose if at continued risk).
— Persons aged >9 months who travel to or reside in countries 
in which meningococcal disease is hyperendemic or 
epidemic, particularly if contact with the local population 
will be prolonged.
• Vaccination of persons in at-risk groups (see Appendix B) 
to control outbreaks.
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B a c k g r o u n d
Meningococcal disease is a bacterial infection caused by 
N .  m e n i n g i t i d i s .  Meningococcal disease usually presents 
clinically as one of three syndromes: meningitis (50.2%), 
bacteremia (37 .5% ), or bacteremic pneumonia (9.2%) (15). 
N .  m e n i n g i t i d i s  colonizes mucosal surfaces of the nasopharynx 
and is transmitted through direct contact with large-droplet 
respiratory tract secretions from patients or asymptomatic 
carriers. Nasopharyngeal carriage rates are highest in 
adolescents and young adults ( 16, 17) ,  who serve as reservoirs 
for transmission of N .  m e n i n g i t i d i s .  Invasive disease is an 
infrequent consequence of nasopharyngeal colonization.
E p id e m io lo g y  o f  M e n in g o c o c c a l  D is e a s e
During 2005- 2011, an estimated 800- 1,200 cases of 
meningococcal disease occurred annually in the United States, 
representing an incidence of 0.3 cases per 100,000 population 
(C D C , unpublished data, 2012). Incidence has declined 
annually since a peak of disease in the late 1990s (Figure 1 ). 
Even before routine use of a meningococcal conjugate vaccine 
in adolescents was recommended in 2005, the overall annual 
incidence of meningococcal disease had decreased 64%, 
from 1 .1  cases per 100,000 population in 1996 to 0.4 cases 
per 100,000 population in 2005. Since 2005, declines have 
occurred among all age groups and in all vaccine-containing 
serogroups. In addition, incidence of disease attributable to 
serogroup B , a serogroup not included in the vaccine, declined
FIGURE 1. Rate* of meningococcal disease, by year —  United States, 
1970-2011+
Year
Source: CDC, Unpublished data, National Notifiable Diseases Surveillance 
System (NNDSS) for 1970-1996 and Active Bacterial Core surveillance (ABCs) 
system for 1997-2011.
* Per 100,000 population.
f ABCs cases from 1997-2011 estimated to the U.S. population. In 2010, 
estimated case counts from ABCs were lower than cases reported to NNDSS 
and might not be representative.
for reasons that are not known. Although disease incidence 
is at historic lows, the overall case-fatality ratio remains at 
10%—15%, and 11%—19% of survivors have long-term 
sequelae (e.g., neurologic disability, limb or digit loss, and 
hearing loss) ( 15, 18, 19) .
Serogroups B, C , and Y are the major causes of meningococcal 
disease in the United States, each accounting for approximately 
one third of cases. However, the proportion of cases caused 
by each serogroup varies by age group. Approximately 60% of 
disease among children aged 0 through 59 months is caused 
by serogroup B  N .  m e n i n g i t i d i s ,  which is not prevented by 
currently licensed vaccines (Table 1 ) (15). Serogroups C , Y, 
or W, which are included in vaccines available in the United 
States, cause 73% of all cases of meningococcal disease among 
persons aged >11 years (CD C , unpublished data, 2012).
In the United States, approximately 98% of cases of 
meningococcal disease are sporadic; however, outbreaks of 
meningococcal disease continue to occur (20). During 2010, 
two serogroup C meningococcal outbreaks were reported to 
CD C (CD C , unpublished data, 2010); in these two instances, 
meningococcal conjugate vaccination was recommended for 
a target age group in the community by local and state health 
officials as a control measure. These outbreaks ended shortly 
after vaccination campaigns were implemented, but whether 
vaccination prevented additional cases from occurring is 
unknown (21). In 2010, two serogroup B outbreaks also were 
reported to CD C. Cases associated with all reported outbreaks 
accounted for 108 (1.5%) of the 7,343 cases reported to CDC 
during 2005-2011 (CD C , unpublished data, 2012).
Incidence of meningococcal disease peaks among persons in 
three age groups: infants and children aged <5 years, adolescents 
and young adults aged 16 through 21 years, and adults aged 
>65 years (CD C , unpublished data; Table 2 ; Figure 2). The 
highest incidence in the first 5 years of life occurs among infants 
aged 0 through 5 months; 47% of serogroup C and Y  disease 
among children aged 0 through 59 months occurs before age 
6 months. Approximately 60% of disease in the first year of 
life is caused by serogroup B. Licensure in 2005 of the first 
MenACWY vaccine made it possible to address the second 
peak in disease incidence, which occurs in late adolescence. The 
third peak in incidence occurs among adults aged >65 years; 
approximately 60% of these cases are caused by serogroup Y, 
and 43% are characterized by bacteremic pneumonia. The 
highest case-fatality ratio (23.8%) is observed among adults 
aged >65 years (15).
P o s t l i c e n s u r e  I m p a c t  o f  M enA C W Y
Since 2006, the National Immunization Survey-Teen (22) 
has assessed vaccination coverage annually among adolescents
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TABLE 2. Average annual estimated number and rate* of cases of meningococcal disease, by age group and serogroup —  United States, 
2002-2011+
Age group
Serogroup B Serogroup C Serogroup Y Other5 Total
No. (Rate) No. (Rate) No. (Rate) No. (Rate) No. (Rate)
< 1 yr 117 (2.8) 14 (0.3) 38 (0.9) 8 (0.2) 177 (4.B)
0-5 mos 74 (3.6) 5 (0.3) 23 (1.1) 6 (0.3) 108 (S.B)
6-11 mos 43 (2.1) 9 (0.4) 15 (0.7) 2 (0.1) 69 (B.4)
1 yr 28 (0.7) 9 (0.2) 2 (0.1) 3 (0.1) 42 (1.0)
2-4 yrs 38 (0.3) 16 (0.1) 8 (0.1) 7 (0.1) 69 (0.6)
5-10 yrs 31 (0.1) 16 (0.1) 12 (0) 3 (0) 62 (0.B)
11-18 yrs 28 (0.1) 43 (0.1) 43 (0.1) 10 (0) 124 (0.4)
19-21 yrs 26 (0.2) 23 (0.2) 16 (0.1) 3 (0) 68 (0.S)
22-24 yrs 21 (0.2) 22 (0.2) 7 (0.1) 1 (0) S1 (0.4)
25-64 yrs 93 (0.1) 129 (0.1) 125 (0.1) 21 (0) B68 (0.2)
>65 yrs 20 (0.1) 33 (0.1) 114 (0.3) 19 (0.1) 186 (0.S)
Total 402 (0.1) B0S (0.1) B6S (0.1) 76 (0) 1,146 (0.4)
Source: CDC, Unpublished data, Active Bacterial Core surveillance (ABCs) system, 2002-2011.
* Per 100,000 population.
1 ABCs cases from 2002-2011 estimated to the U.S. population with 18% correction for underreporting. In 2010, estimated case counts from ABCs were lower than 
cases reported to the National Notifiable Diseases Surveillance System and might not be representative.
§ Includes serogroup W135, nongroupable, and other serogroups.
aged 13 through 17 years. Among this age group, coverage with 
MenACWY has increased from 10.2% in 2006 to 70.5% in 
2011  (22,23); coverage by state in 2011  ranged from 27.6% 
to 92. 1% (23). One method for assessing the impact of 
MenACWY is to monitor changes in disease incidence caused 
by vaccine serogroups. During 2005- 2009, MenACWY-D 
was the only meningococcal conjugate vaccine licensed in the 
United States. Therefore, postlicensure data primarily reflect 
use of MenACWY-D. During 2009 and 2010, when routine 
vaccine use was recommended and supply was sufficient, 
incidence of serogroup C and Y  meningococcal disease declined 
among adolescents aged 11 through 18 years. Incidence did 
not decline in other age groups, suggesting an impact of 
vaccination on adolescent disease, but no evidence of herd 
protection (Table 3).
During 2006-2010 (i.e., in the first 5 years after routine 
use of meningococcal vaccine was recommended), CD C 
received reports of approximately 30 cases of serogroups 
C and Y  meningococcal disease among persons who had 
received the vaccine. The case-fatality ratio was similar among 
persons who had received vaccine compared with those who 
were unvaccinated (C D C , unpublished data, 20 12 ). To 
assess vaccine effectiveness among adolescents, CD C carried 
out a simulation study of breakthrough disease (i.e., cases 
that occur among vaccine recipients) and a case-control 
study (24,25). The first estimate of vaccine effectiveness was 
based on a simulation approach that calculated the expected 
number of cases in vaccinated persons. The expected number 
of breakthrough cases was calculated from available vaccine 
coverage and disease incidence data, and estimates of expected 
vaccine effectiveness were based on prelicensure serologic 
evidence of immune response. When the number of expected
cases was compared with the observed number of breakthrough 
cases, vaccine effectiveness during 2005—2008 was estimated to 
be 80%—85% ( 24) .  O f the 13 reports of breakthrough disease 
for which data on underlying conditions were available, four 
persons had underlying conditions or behaviors associated 
with an increased risk for bacterial infections, including 
1 ) Type 1 diabetes mellitus; 2) current smoking; 3) history of 
bacterial meningitis and recurrent infections; and 4) aplastic 
anemia, paroxysmal nocturnal hemoglobinuria, and receipt 
of eculizumab (which blocks complement protein C 5) (24).
A  case-control study evaluating the vaccine effectiveness 
of meningococcal conjugate vaccine in adolescents began in 
January 2006 (25) .  Because MenACWY-D was the only licensed 
conjugate vaccine until February 2010, the preliminary results 
provided in this report are estimates for MenACWY-D only. As of 
August 29, 2012, a total of157 case-patients and 180 controls were 
enrolled in the effectiveness study. The overall estimate of vaccine 
effectiveness in adolescents vaccinated 0 through 6 years earlier 
was 69% (95% confidence interval [CI] = 50%—81%). Vaccine 
effectiveness was 82% (CI = 54%—93%) for adolescents vaccinated 
<1 year earlier, 80% (CI = 52%—92%) for adolescents vaccinated
1—<2 years earlier, 71% (CI = 34%—87%) for adolescents vaccinated
2—<3 years earlier, and 59% (CI = 5%—83%) for adolescents 
vaccinated 3—<6 years earlier (25). Although CIs around the point 
estimates are wide, these results suggest that vaccine effectiveness 
wanes over time.
R isk  F a c to rs  f o r  M e n in g o c o c c a l  D is e a s e
Risk factors for meningococcal disease can be grouped into 
organism, host, and environmental factors. Noncapsular strains 
of N .  m e n i n g i t i d i s  are less virulent than capsular strains. More
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demonstrated that blacks and persons of low socioeconomic 
status were at higher risk for meningococcal disease than other 
persons (37,38); however, race and low socioeconomic status also 
are considered markers for other risk factors (e.g., smoking and 
household crowding) (31). As disease incidence has decreased, 
differences by race also have decreased, and no difference in disease 
incidence exists now between blacks and whites (15).
One study of meningococcal disease among clinical 
microbiologists who work routinely with N .  m e n i n g i t i d i s  
isolates demonstrated an attack rate of 13 cases per 100,000 
microbiologists and increased case-fatality ratios. O f the 16 
cases identified, 15 occurred in clinical microbiologists who 
were not using respiratory protection at the time of exposure
( 39. 40) .  Health-care personnel in general are not identified 
as a high-risk group unless a person is exposed to respiratory 
secretions of someone with meningococcal disease.
Because the incidence of both meningococcal disease and H IV 
infection are low in the United States, studies have not established 
H IV as an independent risk factor for meningococcal infection
(32. 41) .  A  recent study in the ABCs sites demonstrated that the 
cumulative average incidence of meningococcal disease among 
patients aged 25 through 64 years who meet CDC’s surveillance case 
definition for acquired immune deficiency syndrome (AIDS) was 
3.5 cases per 100,000 person years (CI = 2.0- 5.6), compared with 
an incidence of0.3 cases per 100,000 person years (CI = 0.2- 0.3) for 
persons of the same age group in the general population (rate ratio: 
12 .6; C I = 7 .9- 20.2) (42). These incidence rates were not adjusted 
for potential confounding risk factors such as smoking; however, 
the incidence of meningococcal disease is higher in persons with 
AIDS compared with the general adult population.
M e n in g o c o c c a l  D is e a s e  
A m o n g  C o l le g e  S t u d e n t s
Studies conducted in the 1990s that focused on quantifying the 
risk for meningococcal disease among college students demonstrated
TABLE 3. Rate* of meningococcal disease, by age group and serogroup —  United States, 1998-2011 +
Years
Serogroup C, Y, W Serogroup B
<1 yr 11-19 yrs >20 yrs <1 yr 11 -19 yrs >20 yrs
Rate (CI) Rate (CI) Rate (CI) Rate (CI) Rate (CI) Rate (CI)
1998-1999 5.86 (4.24-7.90) 1.13 (0.90-1.41) 0.47 (0.41-0.54) 3.32 (2.21-4.86) 0.22 (0.13-0.36) 0.14 (0.11-0.19)
2000-2001 2.32 (1.45-3.55) 0.71 (0.54-0.91) 0.38 (0.33-0.44) 4.30 (3.02-5.95) 0.27 (0.17-0.41) 0.13 (0.10-0.17)
2002-2003 2.06 (1.23-3.26) 0.55 (0.40-0.73) 0.25 (0.21-0.30) 4.30 (3.06-5.90) 0.20 (0.12-0.32) 0.11 (0.09-0.15)
2004-2005 0.77 (0.33-1.55) 0.27 (0.17-0.39) 0.17 (0.14-0.21) 3.10 (2.10-4.42) 0.11 (0.06-0.20) 0.07 (0.05-0.09)
2006-2007 1.20 (0.61-2.11) 0.31 (0.21-0.45) 0.23 (0.19-0.28) 2.11 (1.32-3.22) 0.05 (0.02-0.12) 0.06 (0.04-0.09)
2008-2009 0.93 (0.48-1.69) 0.15 (0.08-0.26) 0.23 (0.19-0.27) 2.92 (1.99-4.18) 0.10 (0.04-0.18) 0.07 (0.05-0.10)
2010-2011 1.37 (0.74-2.33) 0.05 (0.02-0.12) 0.14 (0.11-0.18) 1.33 (0.72-2.29) 0.00 (0.00-0.05) 0.03 (0.02-0.05)
Abbreviation: CI = 95% confidence interval.
Source: CDC, Unpublished data, Active Bacterial Core surveillance (ABCs) system, 1998-2011.
* Per 100,000 population.
f ABCs cases from 1998-2011 estimated to the U.S. population with 18% correction for nonculture-confirmed cases. In 2010, estimated case counts from ABCs were 
lower than cases reported to the National Notifiable Diseases Surveillance System and might not be representative.
FIGURE 2. Rate* of meningococcal disease, by age group —  United
States, 2002-2011 +
Age group (yrs)
Source: Unpublished data, Active Bacterial Core surveillance (ABCs) system.
* Per 100,000 population.
f ABCs cases from 2002-2011 estimated to the U.S. population with 18% 
correction for nonculture-confirmed cases. In 2010, estimated case counts 
from ABCs were lower than cases reported to the National Notifiable Diseases 
Surveillance System and might not be representative.
virulent strains of N .  m e n i n g i t i d i s  can circulate in a population 
and cause increased incidence of disease or increased mortality 
(26). Persons who have persistent (i.e., genetic) deficiencies in 
the common complement pathway (e.g., C3, properdin, Factor 
D , Factor H , or C 5-C 9) have up to a 10,000-fold increased risk 
for meningococcal disease and can experience recurrent disease 
( 27, 28) .  Although persons with anatomic or functional asplenia 
also appear to be at increased risk for meningococcal disease, the 
data are less compelling than data that demonstrate the increased 
risk for pneumococcal disease in patients with asplenia (29).
Antecedent viral infection, household crowding, chronic 
underlying illness, and both active and passive smoking are 
associated with increased risk for meningococcal disease (30—36). 
Early U.S. studies of risk factors for meningococcal disease
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that the overall incidence among college students was similar to or 
somewhat lower than that observed among persons ofapproximately 
the same age in the general population (43). However, in a case- 
control study involving 50 cases among college students ( 44) ,  
multivariate analysis indicated that first-year college students living 
in residence halls were at higher risk for meningococcal disease than 
other students (matched odds ratio [OR]: 3.6; C I = 1.6—8.5). Other 
studies in the 1990s yielded similar results ( 45, 46) .
In 2000, before licensure of meningococcal conjugate 
vaccines, A C IP  recommended that first-year college 
students living in residence halls consider vaccination with 
the quadrivalent meningococcal polysaccharide vaccine 
(MPSV4), which was licensed in 1981 ( 47) .  Since the 2000 
A C IP  recommendation, many colleges have required all 
matriculating students to be vaccinated. Thirty-six states and 
the District of Columbia have mandates requiring education 
of college students about meningococcal vaccines or proof of 
meningococcal vaccination for attendance (a list of these states 
is available at http://www.immunize.org/laws/menin.asp). 
When the first meningococcal conjugate vaccine was licensed 
in 2005, ACIP recommended that all first-year college students 
living in residence halls be vaccinated with MenACWY-D (1).
M e n i n g o c o c c a l  V a c c i n e s
Four meningococcal vaccines that contain purified capsular 
polysaccharide(s) alone or that are conjugated to a carrier 
protein are licensed and available in the United States for 
the prevention of invasive disease caused by N .  m e n i n g i t i d i s  
serogroups A, C , W and Y  (Table 1). As stated in the package 
inserts (Table 1 ), for the quadrivalent meningococcal 
polysaccharide vaccine (MPSV4), effectiveness of the vaccine 
(A and C components) was supported by clinical efficacy 
data from studies with meningococcal monovalent A  and C 
and bivalent A/C polysaccharide vaccines, and inferred by 
use of serum bactericidal antibody assay (SBA) (Y and W 
components) as an indicator of protection against serogroup- 
specific meningococcal disease. Effectiveness of the three 
meningococcal conjugate vaccines, which were licensed after 
MPSV4, was inferred by comparing SBA measurements of 
the new vaccine with corresponding antibody responses of the 
U.S.-licensed meningococcal vaccine representing the standard 
of care at the time (among persons aged 2 through 55 years) or 
by achieving a seroresponse at or above a predefined bactericidal 
antibody titer (among children aged 2 through 23 months).
I m m u n o lo g ic  S u r r o g a t e  o f  P r o te c t io n
Protection against invasive meningococcal disease is 
mediated by serum bactericidal antibodies to meningococcal
capsular polysaccharides or to protein antigens. Studies have 
demonstrated that almost all persons who developed invasive 
serogroup C meningococcal disease had sera that lacked 
bactericidal activity to the pathogenic meningococcal strain 
( 48, 49) .  In contrast, persons with detectable SBA against a 
specific strain rarely developed disease.
Complement-dependent bactericidal activity can be 
measured reliably by use of a serum bactericidal antibody assay 
with a human (hSBA) or baby rabbit (rSBA) complement 
source. A  defined bactericidal antibody titer that is indicative 
of protection against invasive meningococcal disease is assay- 
dependent. When sera are tested using a human complement 
source, SBA titers >1:4 are considered protective. Because 
of greater susceptibility of meningococci to lysis by rabbit 
complement, antibody titers measured by an rSBA assay are 
elevated compared with titers generated by an hSBA assay 
( 50— 52) .  Population-based surveillance data from the United 
Kingdom indicate that following mass vaccination with 
meningococcal serogroup C conjugate vaccine, bactericidal 
titers between 1:8 and 1:64, measured by rSBA, can be 
protective ( 53) .  Antibody titers measured by rSBA and hSBA 
assays are not directly comparable.
M e n in g o c o c c a l  Q u a d r iv a l e n t  
P o ly s a c c h a r id e  V a c c in e  (M PSV 4)
M PSV4 , a quadrivalent (serogroups A , C , Y, and W) 
meningococcal polysaccharide vaccine (Menomune, 
manufactured by Sanofi Pasteur, Inc., Swiftwater, Pennsylvania), 
was licensed in 1981. MPSV4 is approved by FDA for use as a 
single dose in persons aged >2 years. Each dose consists of 50 
[ig of each of the four purified capsular polysaccharides from 
serogroups A, C , W, and Y. MPSV4 is available in single-dose 
(0.5-mL) and 10-dose (5-mL) vials and is administered as a 
subcutaneous injection. Further information is provided in the 
package insert (available at http://www.fda.gov/downloads/ 
BiologicsBloodVaccines/Vaccines/ApprovedProducts/ 
UCM 131653.pdf).
Q u a d r iv a l e n t  M e n in g o c o c c a l  C o n ju g a te  
V a c c in e s  (M enA C W Y )
Conjugation (i.e., covalent coupling) of a meningococcal 
capsular polysaccharide to a protein carrier that contains 
T-lymphocyte epitopes changes the nature of the human 
immune response to the polysaccharide from T-lymphocyte- 
independent to T-lymphocyte-dependent. Conjugation results 
in an improved primary response to the polysaccharide antigen, 
especially in infants, and a stronger anamnestic response (i.e., 
immunologic memory) at reexposure (54). As of July 2012,
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two quadrivalent (serogroups A, C , Y, and W) and one bivalent 
(serogroups C and Y) meningococcal polysaccharide-protein 
conjugate vaccines have been licensed by FDA: MenACWY-D 
(Menactra, manufactured by sanofi pasteur, Inc., Swiftwater, 
Pennsylvania), MenACWY-CRM (Menveo, manufactured 
by Novartis Vaccines, Cambridge, Massachusetts), and Hib- 
M enCY-TT (MenHibrix, manufactured by GlaxoSmithKline 
Biologicals, Rixensart, Belgium).
M enA C W Y -D
MenACWY-D was licensed by FD A in January 2005. 
MenACWY-D is approved by FD A  as a single dose for 
persons aged 2 through 55 years and as a 2-dose series in 
children aged 9 through 23 months. A  single 0.5-mL dose of 
MenACWY-D contains 4 f i g  each of capsular polysaccharide 
from serogroups A, C , Y, and W  conjugated to approximately 
48 f  g of diphtheria toxoid. MenACWY-D is available in single­
dose vials and is administered as an intramuscular injection. 
More information is provided in the package insert (available 
at http://www.fda.gov/downloads/BiologicsBloodVaccines/ 
Vaccines/ApprovedProducts/UCM131170.pdf).
MenACWY-D often will be administered concomitantly with 
other vaccines (e.g., with typhoid vaccines in international travelers 
or with other routinely recommended vaccinations in adolescents 
and young children). As stated in the package insert (Table 1), 
concomitant administration of MenACWY-D and typhoid vaccines 
(Typhoid V i Polysaccharide Vaccine, manufactured by Sanofi 
Pasteur, Inc., Swiftwater, Pennsylvania) was evaluated in persons 
aged 18 through 55 years, and concomitant administration of 
MenACWY-D and Td (Tetanus and Diphtheria Toxoids Adsorbed, 
For Adult Use; manufactured by Sanofi Pasteur, Inc., Swiftwater, 
Pennsylvania) vaccine was evaluated in persons aged 11 through 
17 years. Concomitant administration of typhoid vaccine and 
MenACWY-D did not affect the immunogenicity ofeither vaccine. 
The proportion of participants with a fourfold or greater increase 
in rSBA titer to meningococcal serogroups C, Y, and W  was higher 
when MenACWY-D was administered with Td (86%—96%) 
than when MenACWY-D was administered 1 month following 
administration ofTd (65%—91%). Antitetanus and antidiphtheria 
antibody responses were similar in both study groups.
Affect on immunogenicity varied by vaccine administerd 
concomitantly. Concomitant administration ofMMRV (measles, 
mumps, rubella, and varicella combination vaccine) and the 
fourth dose ofPCV7 (7-valent pneumococcal conjugate vaccine) 
and a second MenACWY-D dose was evaluated in children 
aged 12 months who had received the first MenACWY-D 
dose at age 9 months. Lower geometric mean concentrations 
(GMCs) ofIgG antibodies to some pneumococcal serotypes were 
observed compared with corresponding IgG GMCs when PCV7
was administered alone. The noninferiority criteria (twofold 
differences in IgG GMC) for the prespecified pneumococcal 
endpoints were not met for PCV7 serotypes 4, 6B, and 18C ( 10) .  
However, the IgG antibody responses and opsonophagocytic 
responses to the seven pneumococcal vaccine serotypes were 
still robust. No interference with immune responses to antigens 
contained in MMRV was observed. Details about these studies 
are provided in the package insert.
M enA C W Y -C R M
M enACW Y-CRM  was licensed by FD A  in February 
2010. MenACWY-CRM is approved by FD A as a single 
dose for persons aged 2 through 55 years. A  single 0.5-mL 
dose of vaccine contains 10 f i g  of capsular polysaccharide 
from serogroup A and 5 f  g of capsular polysaccharide from 
serogroups C , Y, and W conjugated to approximately 33-64 f  g 
of CRM 197, a naturally occurring, nontoxic form of diphtheria 
toxin from C o r y n e b a c t e r i u m  d i p h t h e r i a e .  MenACWY- 
CRM  must be prepared by reconstituting the lyophilized 
serogroup A  conjugate with the liquid serogroups C , W, and 
Y  conjugate components. More information is provided in the 
package insert (available at http://www.fda.gov/downloads/ 
BiologicsBloodVaccines/Vaccines/ApprovedProducts/ 
UCM 201349.pdf).
MenACWY-CRM is likely to be administered concomitantly 
with tetanus and diphtheria toxoids and acellular pertussis 
vaccine absorbed (Tdap) because both vaccines are routinely 
recommended for adolescents. Concom itant use of 
MenACWY-CRM and Tdap was evaluated in an open-label, 
randomized, controlled study conducted among adolescents 
aged 11 through 18 years. Antibody responses to pertussis 
antigens were lower when MenACWY-CRM and Tdap were 
administered concomitantly than when MenACWY-CRM 
was administered 1 month following Tdap: antipertussis 
toxin GM Cs were 51 versus 63 E IA  Units (EU )/m L, 
antifilamentous hemagglutinin GMCs were 342 versus 511 
EU/m L, and antipertactin GMCs were 819 versus 1,197 EU/ 
mL, respectively. Because no serologic correlates of protection 
for pertussis have been established, the clinical implications of 
the lower pertussis antigen responses are unknown. Immune 
responses to MenACWY-CRM and to diphtheria and tetanus 
toxoid antigens in Tdap were similar. Details about this 
study are provided in the package insert (available at http:// 
www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ 
ApprovedProducts/UCM201349.pdf).
H ib-M enC Y -T T
Hib-MenCY-TT was licensed by FDA in June 2012. Hib- 
MenCY-TT is approved by FDA as a 4-dose series for children
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aged 6 weeks through 18 months. Hib-MenCY-TT is supplied 
as a sterile, lyophilized powder that is reconstituted at the time 
of use with the accompanying saline diluent for intramuscular 
injection. A  single 0.5mL dose ofvaccine contains 5 f  g ofcapsular 
polysaccharide from serogroups C conjugated to approximately 5 
f  g of tetanus toxoid, 5 f  g of capsular polysaccharide from serogroup 
Y  conjugated to approximately 6.5 f  g of tetanus toxoid, and 2.5 
fg  of H a e m o p h i l u s  i n f l u e n z a e  type b capsular polysaccharide 
conjugated to approximately 6.25 fg  of tetanus toxoid. More 
information is provided in the package insert (available at http:// 
www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ 
ApprovedProducts/UCM308577.pdf).
Concomitant administration with routinely recommended 
vaccines is anticipated. Hib-MenCY-TT was co-administered with 
DTaP-HepB-IPV and 7-valent pneumococcal conjugate vaccine 
(PCV7) at ages 2, 4, and 6 months, and with measles-mumps- 
rubella, varicella, and PCV7 vaccines at age 12—15 months. In clinical 
trials, no decreased immunogenicity ofcoadministered vaccines was 
observed (55,56). A  randomized, controlled, multicenter study 
evaluated the percentage of subjects with hSBA titers >1:8 at 2 
months after the second dose was administered at age 4 months. 
In the group vaccinated with Hib-MenCY-TT, 94% and 83% of 
subjects achieved hSBA antibody titers >1:8 for meningococcal 
serogroups C and Y, respectively, after dose 2 (57) .  Rates of local 
and systemic adverse events observed after administration of Hib- 
MenCY-TT were comparable to rates observed after administration 
of Hib-TT. Thus, Hib-MenCY-TT was found to be safe and 
immunogenic for both Hib and meningococcal serogroups C and Y.
E x p e r ie n c e  w i th  M e n in g o c o c c a l  
P o ly s a c c h a r id e  V a c c in e  (M PSV 4)
The immunogenicity and clinical efficacy of serogroups A  and 
C meningococcal polysaccharide vaccines are well- established. 
The serogroup A  polysaccharide induces antibody response 
among children as young as age 3 months, although a response 
comparable with that occurring in adults is not achieved until age 
4 to 5 years; the serogroup C component is poorly immunogenic 
among recipients aged <24 months ( 58—60) .  The serogroups A 
and C vaccines have demonstrated estimated clinical efficacies 
of >85% among school-aged children and adults during 
outbreaks ( 61—64) .  Although clinical protection has not been 
documented, vaccination with Y  and W polysaccharides induces 
production of bactericidal antibodies ( 65—67) .  The antibody 
responses to each of the four polysaccharides in the quadrivalent 
vaccine are serogroup specific and independent (i.e., there is no 
cross-protection).
Reduced clinical efficacy has not been demonstrated among 
persons who have received multiple doses of polysaccharide 
vaccine. However, serologic studies have indicated that multiple
doses of serogroup A  and C polysaccharide vaccine can cause 
immunologic hyporesponsiveness (i.e., a reduced antibody 
response after subsequent doses with the same polysaccharide 
antigen) to group A  ( 68,69)  and C polysaccharide ( 70,71) .  
Hyporesponsiveness to serogroups C and A  polysaccharides 
can be overcome partially by vaccination with serogroup C or 
A  conjugate vaccine (72).
E x p e r ie n c e  w i th  M e n in g o c o c c a l  
C o n ju g a t e  V a c c in e s
An advantage of vaccines in which proteins are conjugated 
to polysaccharide antigens is their ability to elicit immunologic 
memory. Meningococcal conjugate vaccines prime the immune 
system, and immunologic memory persists even in the absence 
of detectable bactericidal antibodies. However, while vaccine- 
induced immunologic memory might be protective against 
infection with other disease-causing encapsulated bacteria, 
the presence of detectable circulating antibody appears to be 
important for protection against N .  m e n i n g i t i d i s .  In most cases, 
meningococcal infection progresses rapidly, with fulminant 
disease occurring within 1-4 days after invasion of normally 
sterile body sites.
Studies of antibody response kinetics following boosting with 
serogroup C meningococcal vaccines in the United Kingdom 
have demonstrated that up to 10 days might be required to 
achieve protective rSBA titers >1:8 in healthy young adults 
(73). I f  antibody is not present in sufficient quantity before 
colonization, this delay in antibody synthesis might not be 
rapid enough to protect against infection with N .  m e n i n g i t i d i s .  
Analyses of breakthrough disease among previously vaccinated 
persons in the United Kingdom identified evidence of 
immunologic priming but low SBA activity at the time of 
disease onset. Although infected persons demonstrated a 
boost response to N .  m e n i n g i t i d i s  and bactericidal antibody 
levels increased, the response was not rapid enough to prevent 
disease (74). Therefore, circulating bactericidal antibody at the 
time of exposure appears to be critical for protection against 
meningococcal disease.
Meningococcal vaccination coverage has increased in the 
United States, but no evidence of herd protection has been 
demonstrated (75). However, herd protection has been an important 
component associated with long-term protection with use of 
serogroup C meningococcal vaccine in the United Kingdom and 
other countries. Evidence ofherd protection after the MenC vaccine 
program was implemented in the United Kingdom, where catch-up 
campaigns led rapidly to high coverage in all persons aged 2 months 
through 22 years, included reduction in nasopharyngeal carriage of 
serogroup C N .  m e n i n g i t i d i s  and reduction of serogroup C disease 
in unvaccinated age groups (infants too young to be vaccinated and
MMWR /  March 22, 2013 /  Vol. 62 /  No. 2 9
Recommendations and Reports
adults aged >25 years) ( 76, 77) .  One year after introduction ofMenC 
vaccine in the United Kingdom, serogroup C carriage was reduced 
66% among students aged 15 through 17 years (78). Attack rates 
among unvaccinated children aged <1 year in the United Kingdom 
also declined 67% in the 4 years following vaccine introduction.
During 1998- 2009, the incidence of serogroup C disease in the 
United Kingdom in persons aged >25 years decreased from 0.55 
per 100,000 persons to 0.02 per 100,000 persons, and the total 
number of cases in infants aged <3 months decreased from 13 in 
1998 to one in 2009 (79). The vaccination program in the United 
Kingdom effectively eliminated a single highly virulent clone that 
had high expression of the polysaccharide capsule (80). Variability 
of strains, different vaccines, and different target populations likely 
account for the differences in vaccine impact observed to date in 
the United States compared with the United Kingdom.
P e r s i s t e n c e  o f  A n t ib o d ie s  A f te r  
V a c c in a t io n  w i th  M enA C W Y
Longitudinal vaccine effectiveness studies as well as evaluation of 
persistence ofantibody after vaccination with MenACWY vaccines 
are critical to monitoring duration of protection. Persistence of 
detectable bactericidal antibodies 3 years after a single vaccination 
(administered at age 1 1  through 18 years) and antibody responses 
consistent with immunologic boosting have been observed in 
adolescent MenACWY-D recipients. Lower bactericidal antibody 
titers to each of the four serogroups were observed 3 to 5 years 
postvaccination relative to bactericidal antibody responses 
observed 1 month after a single MenACWY dose ( 81, 82) .  For 
serogroup C, geometric mean antibody titers (GMTs) declined 
by as much as 90% over 3 years. The proportion of adolescents 
vaccinated at age 11 years with MenACWY-D determined to have 
protective antibodies 3 years later was 71%—95% (81). Antibody 
persistence following MenACWY-CRM vaccination also has 
been described. Among persons vaccinated with a single dose of 
MenACWY-CRM at age 11 through 18 years, approximately 65% 
maintained hSBA >1:8 for serogroups C and Y  at 21 months and 
36 months postvaccination ( 83, 84) .  These serologic data have 
been summarized (Table 4); the data are consistent with results 
of studies discussed previously in this report that suggest waning 
vaccine effectiveness.
Other serologic studies conducted among infants and young 
children demonstrate a similar decline in hSBA titers. The 
proportion of children aged 2 years with hSBA titers >1:4 6 
months following a single vaccination with MenACWY-D was 
approximately 50% for serogroups C , Y, and W -135 (85, 86). 
In another study, approximately 60 infants were vaccinated 
at age 9 months and at age 12 or 15 months, and hSBA 
titers were measured approximately 3 years after the second 
dose. Fewer than half of the study subjects had maintained
an hSBA titer >1:8 for any of the meningococcal serogroups 
(ACIP, unpublished data, 2011). Among infants who received 
a 4-dose series of Hib-MenCY-TT, 83% and 70% of subjects 
had persistence of bactericidal antibody for serogroups C and 
Y, respectively, 5 years after the fourth dose (87).
I m m u n o g e n ic i ty  a n d  S a f e ty  o f  a  
B o o s te r  D o s e  o f  M enA C W Y
In three separate studies, bactericidal antibody responses after 
a booster dose of MenACWY-D were evaluated in adolescents 3 
years after receiving a MenACWY-D primary dose (administered 
at age 1 1  through 18 years), in children 5 years after receiving a 
MenACWY-D primary dose (administered at age 2 through 10 
years) and after a booster dose ofMenACWY-CRM in adolescents 
3 years after a MenACWY-CRM primary dose (administered 
at age 11 through 18 years) (ACIP, unpublished data, 2009), At 
both 3 and 5 years after the first MenACWY conjugate vaccine 
dose, revaccination with the same MenACWY conjugate vaccine 
elicited substantially higher GMTs compared with the titers 
elicited after a single primary dose. In the MenACWY-D booster 
studies, when rSBA was used as a measure of immune response, a 
dose administered 5 years after the first dose (administered at age 
2 through 10 years) elicited a GM T for serogroup C of 23,613 
compared with 9,045 among meningococcal vaccine-naive subjects 
aged 7 through 15 years who had received a single primary dose 
(ACIP, unpublished data, 2010).
In all ofthe studies, local and systemic reactions following a booster 
dose of either MenACWY conjugate vaccine were comparable with 
reactions in persons receiving a primary dose of the same vaccine. 
The duration ofprotection after a booster dose in adolescents, when 
administered at ages 16 through 18 years, is not known, but expert 
members of the Work Group expect protection to last through at 
least age 21 years. A  booster dose of MenACWY-D in children 
initially vaccinated with MenACWY-D at age 9 months and then 
at age 12 or 15 months was evaluated 3 years after the second 
administered dose. Following booster immunization, at least 98% 
of children achieved an hSBA titer >1:8 to each of the serogroups. 
ACIP evaluated the data available and decided to recommend a 
booster dose ofMenACWY for persons who remained at increased 
risk for meningococcal disease and for adolescents at age 16 years.
I n t e r c h a n g e a b i l i t y  o f  V a c c in e  P r o d u c t  
f o r  t h e  B o o s te r  D o s e
Limited data suggest that different conjugate vaccine 
products can be used interchangeably. The safety and 
immunogenicity of MenACWY-CRM vaccination have been 
evaluated in adolescents 3 years after they received a single 
dose of MenACWY-CRM or MenACWY-D administered at
10 MMWR /  March 22, 2013 /  Vol. 62 /  No. 2
Recommendations and Reports
TABLE 4. Summary of serogroup C bactericidal antibody persistence as determined by 
serum bactericidal antibody assay (SBA) 2 -5  years after vaccination with meningococcal 
vaccines —  United States, 2006-2010







% with protective 
No. antibody levels
11-18* 2 % hSBA >1:8 Menveo 273 62
Menactra 185 58
11-18+ 3 % rSBA >1:128 Menactra 71 75
MPSV4 72 60
2-10+ 5 % rSBA >1:128 Menactra 161 55
MPSV4 207 42
11-18+ 5 % rSBA >1:128 Menactra 50 56
MPSV4 68 62
11-17§ 5 % hSBA >1:8 Menveo 50 72
MPSV4 50 62
Abbreviations: hSBA = SBA using human complement; rSBA = SBA using baby rabbit complement;
MPSV4 = quadrivalent meningococcal polysaccharide vaccine.
* Source: Gill C, Baxter R, Anemona A, Ciavarro G, Dull P. Persistence of immune responses after a single 
dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo) or 
Menactra among healthy adolescents. Human Vaccines 2010;6:881-7.
+ Source: Advisory Committee on Immunization Practices, unpublished data, 2009.
§ Source: Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrljin T, Dull T. Antibody persistence and response 
to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents. Pediatr 
Infect Dis J [Epublished ahead of print]. DOI: 10.1097/INF.0b013e318279ac38.
age 11 through 18 years (88). Following revaccination with 
MenACWY-CRM, >99% of persons previously immunized 
with MenACWY-CRM or MenACWY-D had hSBA titers 
>1 :8. The solicited adverse event rates (including injection-site 
reactions) reported after revaccination were similar to the rates 
reported after primary immunization (88). No data exist on 
the use of MenACWY-D following primary vaccination with 
MenACWY-CRM.
I m m u n e  R e s p o n s e  o f  M e n in g o c o c c a l  
C o n ju g a te  V a c c in e s  in  S p e c ia l  P o p u la t io n s
Asplenic persons are at increased risk for invasive infection 
caused by many encapsulated bacteria, including N .  m e n i n g i t i d i s .  
Moreover, the mortality rate is 40%—70% among these 
persons when they become infected with N .  m e n i n g i t i d i s .  
Asplenic persons achieve significantly lower geometric mean 
rSBA titers than healthy persons after vaccination with a 
meningococcal C conjugate vaccine, with 20% not achieving 
rSBA titers >1 :8. This proportion was reduced to 7% when a 
second dose of vaccine was administered to nonresponders 2 
months later (2), suggesting that a 2-dose primary series might 
be effective in achieving higher circulating antibody levels 
and persistence of bactericidal antibodies. The complement 
pathway is important in prevention of meningococcal disease, 
and N .  m e n i n g i t i d i s  is the primary bacterial pathogen affecting 
persons with inherited late component complement or 
properidin deficiency. Although persons with late-component
complement deficiency are able to mount 
an overall antibody response equal to or 
greater than complement-sufficient persons 
after vaccination with MPSV4, antibody 
titers wane more rapidly in persons with 
complement component deficiency, and 
higher antibody levels are needed for other 
clearance mechanisms, such as opsonization 
to function ( 27, 28) .
Although persons with H IV  infection 
are not at as high a risk for meningococcal 
disease as persons with persistent complement 
component deficiency or asplenia, reduced 
antibody responses following meningococcal 
vaccination have been reported in persons 
with H IV  infection (3, 4). Two studies 
have investigated the response rates to 
M enACW Y-D among H IV-infected 
adolescents and children (3, 4). Among 
HIV-infected adolescents and young adults 
vaccinated with a single dose at age 1 1  through 
24 years, response rates to vaccination measured by rSBA titers 
>1:128 were 86%, 55%, 73%, and 72% for serogroups A, C, 
Y, and W, respectively. Response rates were significantly lower 
among patients with a CD4+ T-lymphocyte percentage of <15% 
(p = 0.003) or viral loads >10,000 copies/mL (p = 0.005) (4).
P o s t l i c e n s u r e  S a f e t y  S u r v e i l l a n c e  f o r  
M e n i n g o c o c c a l  C o n j u g a t e  V a c c i n e s
Surveillance for adverse events following receipt of meningococcal 
conjugate vaccines has been performed primarily by two systems 
in the United States, VAERS and VSD. VAERS is a national 
passive surveillance system operated jointly by CDC and FDA 
that receives reports of adverse events following vaccination from 
health-care personnel, manufacturers, vaccine recipients, and 
others. The VAERS reporting form collects information about 
vaccine recipient demographics, vaccines administered, recipient 
medical history, and signs and symptoms ofadverse events. VAERS 
can generate, but not test, vaccine safety hypotheses and is subject 
to several limitations, including reporting biases and inconsistent 
data quality ( 12. )  Passive surveillance data from VAERS should 
be interpreted with caution. The VSD project is a collaborative 
effort between CDC and 10 managed care organizations. The 
VSD project allows for planned vaccination safety studies as wells 
as timely investigations of hypotheses that arise from review of 
medical literature, reports to VAERS, changes in immunization 
schedules, or introduction of new vaccines (13).
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A d v e r s e  E v e n ts  a f t e r  R e c e ip t  o f  
M e n in g o c o c c a l  C o n ju g a te  V a c c in e
MenACWY-D
From licensure ofMenACWY-D in January 14, 2005, through 
September 30, 2011, VAERS received 8,592 reports involving 
receipt of MenACWY-D in the United States; 89.0% reports 
involved persons aged 11 through 19 years. MenACWY-D was 
administered alone in 22.5% of case reports. The median time 
from vaccination to onset of an adverse event was 1 day. Males 
accounted for 40.6% ofthe reported events. The most frequently 
reported adverse events were fever 16.8%, headache 16.0%, 
injection site erythema 14.6%, and dizziness 13.4%. Syncope 
previously has been identified as an adverse event following 
any vaccination, with a higher proportion of syncope events 
reported to VAERS having occurred in adolescents compared 
with other age groups (89). Syncope was reported in 10.0% of 
reports involving MenACWY-D. Among all MenACWY-D 
reports, 563 (6.6%) were coded as serious (i.e., resulted in 
death, life-threatening illness, hospitalization, prolongation of 
hospitalization, or permanent disability).
Among those reports coded as serious, the most frequent adverse 
events reported included headache (37 .5%), fever (32.5%), 
vomiting (23.6%), and nausea (22.2%). Cases of Guillain-Barre 
Syndrome (GBS) were recorded in 86 (15.3%) reports coded as 
serious, although the diagnosis has not been validated by medical 
records for all reports. A  total of 24 (0.3%) deaths were reported, 
each ofwhich was documented by autopsy report or other medical 
records and occurred in persons aged 10 through 23 years.
Among the 24 reports of death, 11 (45.8%) indicated that the 
cause of death was meningococcal infection (nine with a serogroup 
included in the vaccine and two with a nonvaccine serogroup). 
Among the other 13 (54.2%) reports of death, which occurred 
from the day of vaccination to 127 days following vaccination, 
stated causes of death were cardiac (five), neurologic (two), 
infectious (two), behavioral (i.e., suicide) (two), rheumatologic 
(one), and unexplained (one). There was no pattern among 
these reports. Except for the finding of GBS, which was further 
evaluated and is discussed below, no signals were identified in 
VAERS after MenACWY-D vaccination.
MenACWY-CRM
During February 19, 2010-September 30, 2011, VAERS 
received 284 reports of adverse events following receipt of 
MenACWY-CRM in the United States. Approximately three 
fourths (78.9%) of the reported events concerned persons aged 
11 through 19 years. Males were the subject of 44.0% of reports; 
45.4% of reports involved other vaccines administered at the 
same time, and 4.2% of reports were coded as serious. One death 
was reported, with the cause of death stated as unexplained. The
median time from vaccination to adverse event onset was 0 days 
(the day ofvaccination). The most common adverse event reported 
was injection-site erythema (19.7%) followed by injection-site 
swelling (13.7%). Syncope was reported in 8.8% of reports. No 
cases of GBS were reported. Administration errors (e.g., wrong 
diluent used or subcutaneous injection) without adverse events 
were described in 15.5% ofreports involving MenACWY-CRM.
G u illa in -B a r ré  S y n d r o m e  a n d  
M e n in g o c o c c a l  C o n ju g a t e  V a c c in e
In 2005, shortly after licensure ofMenACWY-D, several cases 
of Guillain-Barré Syndrome (GBS) were reported to VAERS 
(90, 91) .  Symptom onset clustered approximately 14 days after 
vaccination with MenACWY-D. No deaths were reported, and 
most persons recovered fully. ACIP reviewed the data at the 
time and determined that the potential small increased risk for 
GBS post-MenACWY-D vaccination was outweighed by the 
protection that the vaccine offers against meningococcal disease 
(92). However, because the risk for recurrence of GBS after 
meningococcal vaccination was unknown, FDA considered 
previous history of GBS a contraindication for use of this 
vaccine ( 93) .  A  large retrospective cohort study of adolescents 
aged 1 1  through 21 years that was conducted during 2005­
2008 included approximately 1.4 million persons vaccinated 
with MenACWY-D (94). In an analysis that took into account 
the missing data, estimates of the attributable risk for GBS 
ranged from zero to 1.5 additional cases of GBS per 1 million 
vaccines within the 6-week period following vaccination 
(http://www.fda.gov/downloads/BiologicsBloodVaccines/ 
Vaccines/ApprovedProducts/UCM131170.pdf).
VSD conducts near-real time surveillance for adverse events 
and tests vaccine safety hypotheses (13). The system collects 
medical care and vaccination information on approximately 
9 m illion members. VSD  uses Rapid Cycle Analysis to 
monitor vaccine safety in near real-time. Each week, the 
number of outcomes in vaccinated persons is compared with 
the expected number of outcomes in the comparison group 
using maximized sequential probability ratio testing (95). 
No cases of GBS were identified within 1-42 days following 
889,684 vaccine doses of MenACWY-D administered during 
January 2005-March 2010 (ACIP, unpublished data, 2010).
In June 2010, after reviewing the two safety studies, ACIP 
voted to remove the precaution for persons with a history of GBS 
because the benefits of meningococcal vaccination outweigh 
the risk for recurrent GBS in these persons. A  history of GBS 
continues to be listed as a precaution in the package inserts for 
MenACWY-D (available at http://www.fda.gov/downloads/ 
BiologicsBloodVaccines/Vaccines/ApprovedProducts/ 
UCM 131170.pdf) and MenACWY-CRM (available at http://
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www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ 
ApprovedProducts/UCM201349.pdf). Since the June 2010 
ACIP meeting, no specific concerns have been raised about 
the risk for GBS in persons who both have a history of this 
condition and have been vaccinated with meningococcal 
conjugate vaccine (96).
S a f e ty  o f  M e n in g o c o c c a l  C o n ju g a te  
V a c c in e  in  P r e g n a n c y
During January 1, 2005-June 30, 2010, a total of 80 reports 
were submitted to VAERS regarding pregnant women or infants 
born to women who received MenACWY-D during pregnancy. 
The majority (57.5%) of women were vaccinated in the first 
trimester (0 through 13 weeks of gestation). Thirty-three 
(41.3%) reports indicated no adverse events, and the reason 
for submitting the report to VAERS was vaccine exposure 
during pregnancy (pregnancy category C)̂ . No maternal deaths 
were reported. The most common pregnancy-specific adverse 
event was spontaneous abortion (12 cases; 15%) and the most 
common nonpregnancy specific adverse event was nausea, with 
or without vomiting (four cases; 5%). One case of a congenital 
anomaly (aqueductal stenosis with severe ventriculomegaly in 
a newborn) was reported. However, no concerning patterns of 
adverse events after MenACWY-D in pregnancy were identified.
P o s t l i c e n s u r e  S a f e ty  o f  
C o a d m in i s t r a t io n  w i th  T d a p
Two postlicensure studies have evaluated use of Tdap when 
administered simultaneously or sequentially with MenACWY 
(97,98). In a clinical trial to evaluate administration of one Tdap 
product (Boostrix, GSK) and MenACWY-D, immune responses 
to the meningococcal serogroups and to pertussis, diphtheria, and 
tetanus were similar regardless of whether the two vaccines were 
administered simultaneously or separated by 30 days. There were 
no differences in the safety evaluation in either of the groups. In 
a postlicensure surveillance study using VSD data, the risk for 
medically attended adverse events was low (0- 2.6 per 10,000 
vaccinations) and similar regardless of whether persons received 
Tdap and MenACWY simultaneously or sequentially (98).
C o s t - E f f e c t i v e n e s s  A n a l y s e s
As part ofthe evaluation ofthe adolescent vaccination program, 
a cost-effectiveness analysis was performed to compare the cost- 
effectiveness of the following three vaccination strategies: 1 ) a
 ̂FDA classification categories available at h ttp ://chem m .nlm .n ih .gov/ 
pregnancycategories.htm
single dose at age 1 1  years, 2) a single dose at age 15 years, and 3) 
a dose at age 11 years with a booster dose at age 16 years (ACIP, 
unpublished data, 2010). The economic costs and benefits of 
these meningococcal vaccination strategies in adolescents were 
assessed from a societal perspective (99, 100) .
A multivariable analysis was performed with a Monte 
Carlo simulation in which multiple parameters were varied 
simultaneously over specified probability distributions. These 
parameters included disease incidence (46% -120% of the 
10-year average), case-fatality ratio (34%—131% of the 10-year 
average), rates of long-term sequelae, acute meningococcal 
disease costs (i.e., inpatient care, parents’ work loss, public health 
response, and premature mortality costs), lifetime direct and 
indirect costs of meningococcal disease sequelae (i.e., long-term 
special education and reduced productivity), and cost of vaccine 
and vaccine administration (range: $64—$114). Vaccination 
coverage (37% -90%) and initial vaccine efficacy (39% -99%) 
also were varied for evaluation purposes. The vaccine was 
assumed to be 93% effective in the first year, and then waning 
immunity was modeled as a linear decline over the next 9 years 
unless a booster dose was administered. The vaccine effectiveness 
of the second dose was assumed to be higher with a slower 
rate of waning immunity. The results of the cost-effectiveness 
analysis indicate that a 2-dose series at ages 1 1  years and 16 
years has a similar cost-effectiveness compared with moving the 
single dose to age 15 years or maintaining the single dose at 11  
years. However, the number of cases and deaths prevented is 
substantially higher with the 2-dose strategy (Table 5).
R a t i o n a l e  f o r  R e c o m m e n d a t i o n s  f o r  
U s e  o f  M e n i n g o c o c c a l  V a c c i n e s
Meningococcal disease can cause severe and devastating 
illness. Disease incidence is low and has decreased since the 
late 1990s before widespread vaccination of adolescents with 
MenACWY. Meningococcal disease occurs in all age groups, 
with an overall incidence in 2011  of 0.2 cases per 100,000 
population. The burden of disease is highest among infants 
aged <1 year (2.6 cases per 100,000 persons), young adults 
aged 16 through 21 years (0.4 cases per 100,000 persons), and 
persons aged >65 years (0.3 cases per 100,000 persons) (CDC, 
unpublished data, 2012). Among infants, disease incidence 
peaks within the first 6 months of life, and most cases in this 
age group are caused by serogroup B (see Future Meningococcal 
Vaccines, Areas for Research, and Public Education). Rates of 
nasopharyngeal carriage are highest in adolescents and young 
adults ( 16, 17) ,  and adolescents are likely the main source of 
transmission of the organism to persons in other age groups.
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TABLE 5. Summary of cost-effectiveness analyses of different strategies for adolescent vaccination —  United States
Dosage
Cases averted Deaths averted QALY saved Cost per QALY saved ($)
No. (Range) No. (Range) No. (Range) No. (Range)
1 dose at 11 yrs 94 (43-165) 11 (5-20) 736 (330-1,130) 256,000 (84,000-650,000)
1 dose at 15 yrs 115 (51-205) 14 (6-25) 850 (390-1,380) 219,000 (63,000-600,000)
1 dose at 11 yrs with booster dose at 16 yrs 184 (92-308) 22 (11-40) 1,442 (610- 2,130) 212,000 (67,000-535,000)
Abbreviation: QALY = quality-adjusted life years.
Source: Unpublished data with updated estimates, Advisory Committee on Immunization Practices (ACIP) meeting, October 2010. Methods described in Shepard 
CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics
2005;115:1220-32.
The vaccines licensed currently are recommended routinely 
for adolescents and other persons at increased risk for 
meningococcal disease. After licensure of the first MenACWY 
vaccine in 2005, the initial supply ofvaccine was not sufficient 
to vaccinate all adolescents. ACIP prioritized vaccination for 
persons aged 1 1  or 12  years, persons entering high school, and 
first-year college students living in residence halls. Two years 
later, in 2007, after reviewing information on the adequacy 
of vaccine supply, ACIP expanded its recommendation for 
routine 1 -dose vaccination at the earliest opportunity for 
all adolescents aged 11 through 18 years. At the time, some 
experts predicted that the vaccine would be effective for up to 
10 years, providing protection through the period of highest 
risk in late adolescence and early adulthood.
Since the 2005 ACIP recommendations, additional data 
have led to improved understanding of meningococcal 
conjugate vaccines, including new data on duration ofvaccine- 
induced immunity. Antibody persistence studies indicate that 
circulating antibody declines 3 to 5 years after a single dose of 
MenACWY. In addition, results from a vaccine effectiveness 
study demonstrate waning effectiveness, and many adolescents 
are not protected 5 years after vaccination. ACIP concluded that 
a single dose of meningococcal conjugate vaccine administered 
at age 1 1  or 12  years is unlikely to protect most adolescents 
through the period of increased risk at ages 16 through 21 years. 
On the basis of this information, in 2010, ACIP considered 
two options to optimize protection through late adolescence 
into early adulthood: 1 ) moving the single recommended 
dose to age 15 years or 2) retaining the recommended dose at 
ages 1 1  or 12  years and adding a booster dose at age 16 years. 
The benefits of the booster dose and a desire to continue to 
protect younger adolescents prompted the recommendation 
for a routine booster dose at age 16 years (7).
In 2010, AC IP revised the recommendations for dosing 
regimens (e.g., primary series and booster doses) for persons 
who have functional or anatomic asplenia, who have persistent 
complement component deficiencies, or who have H IV  
infection and are otherwise recommended to be vaccinated. For 
these immunosuppressed persons, a 2-dose primary series was 
recommended instead of a single dose (7). For persons with
persistent complement component deficiency, a 2-dose primary 
series will help achieve the high levels of SBA needed to confer 
protection in the absence of effective opsonization. For persons 
with asplenia or HIV, a 2-dose primary series will increase the 
likelihood of a sufficient primary immune response. Booster doses 
after primary vaccination are important for persons with prolonged 
increased risk (persons with asplenia, persons with complement 
component deficiencies, and microbiologists) to ensure high levels 
of SBA are maintained over time.
In 2011 and 2012, ACIP voted to recommend meningococcal 
vaccination for children aged 2 through 23 months who are at 
increased risk for disease. ACIP does not recommend routine 
vaccination of children aged <10 years. The number of infants 
and young children who are or will be at increased risk for 
meningococcal disease is limited. ACIP reviewed the burden 
of meningococcal disease among infants and children aged <10 
years. In the United States, during 1993- 2011, average annual 
rates of meningococcal disease were higher among children aged 
<59 months. However, approximately 60% of disease among 
children aged <59 months is caused by serogroup B N .  m e n i n g i t i d i s  
which is not prevented by Hib-MenCY-TT or MenACWY-D. In 
addition, the highest incidence in the first 5 years of life occurs 
in infants aged 0 through 6 months, many of whom are too 
young to have received the minimum 2 or 3 doses of vaccine 
that likely are needed to provide protection. O f the 205 cases of 
meningococcal disease in children aged <59 months that occur 
annually, it is estimated that a universal infant meningococcal 
vaccination program would prevent 40-50 cases (approximately 
25% of cases in this age group) (CDC, unpublished data, 2012). 
The epidemiology ofmeningococcal disease is dynamic, and rates 
of disease could increase in the future requiring a reassessment of 
immunization strategy.
R e c o m m e n d a t i o n s  f o r  U s e  o f  
M e n i n g o c o c c a l  V a c c i n e s
R o u t in e  V a c c in a t io n  o f  A d o le s c e n t s
ACIP recommends routine administration of a MenACWY 
vaccine for all persons aged 11 through 18 years (Table 6). A  single
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TABLE 6. Recommended meningococcal vaccines for use in children 
and adults —  Advisory Committee on Immunization Practices (ACIP), 
United States, 2012

















Not routinely recommended; see 
Table 7 for persons at increased risk
Not routinely recommended; see 
Table 7 for persons at increased risk
Not routinely recommended; see 
Table 7 for persons at increased risk
Primary:
• Age 11-12 yrs, 1 dose
• Age 13-18 yrs, 1 dose if not
vaccinated previously
• Age 19-21 yrs, not routinely
recommended but may be 
administered as catch-up 
vaccination for those who have 
not received a dose after their 
16th birthday 
Booster:
• 1 dose recommended if first dose
administered before 16th birthday
Not routinely recommended; see 
Table 7 for persons at increased risk
Not routinely recommended; see 
Table 7 for persons at increased risk
Source: Adapted from American Academy of Pediatrics. Meningococcal 
infections. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red book: 2012 
report of the Committee on Infectious Diseases. 29th ed. Elk Grove, IL: American 
Academy of Pediatrics; 2012:500-9.
* Licensed only for persons aged 9 months-55 years.
f Licensed only for persons aged 2-55 years. Under investigation for use at ages 
2, 4, 6, and 12-15 months.
§ Licensed only for children aged 6 weeks-18 months.
dose of vaccine should be administered at age 1 1  or 12 years, and 
a booster dose should be administered at age 16 years. Adolescents 
who receive their first dose at age 13 through 15 years should receive 
a booster dose at age 16 through18 years. The minimum interval 
between doses of MenACWY is 8 weeks. Adolescents who receive 
a first dose after their 16th birthday do not need a booster dose 
unless they become at increased risk for meningococcal disease. 
Persons aged 19 through 21 years are not recommended routinely 
to receive MenACWY. MenACWY may be administered up to age 
21 years as catch-up vaccination for those who have not received 
a dose after their 16th birthday. Health-care personnel should use 
every opportunity to provide the booster dose when indicated, 
regardless of the vaccine brand used for the previous dose or doses.
R e c o m m e n d a t io n s  f o r  S p e c ia l  P o p u la t io n s  
a n d  P e r s o n s  a t  I n c r e a s e d  R isk  fo r  
M e n in g o c o c c a l  D is e a s e
Persons at increased risk for meningococcal disease also 
are recommended for routine meningococcal vaccination 
(Tables 6 and 7). Vaccine product, number of doses, and
booster dose recommendations are based on age and risk factor 
and are described below in detail for each risk group. In general:
• Infants aged 2 through 18 months. Routine vaccination 
w ith H ib-M enCY-TT (4-dose prim ary series) is 
recommended for infants aged 2 through 18 months who 
are at increased risk for meningococcal disease. The first 
dose of Hib-MenCY-TT may be administered as early as 
age 6 weeks. The fourth dose may be administered as late 
as age 18 months. Catch-up vaccination for Hib- 
MenCY-TT is the same as for other Hib-containing vaccines 
(available at http://www.cdc.gov/vaccines/schedules/hcp/ 
child-adolescent.html) with the following exception. I f  the 
first dose of Hib-MenCY-TT is administered at or after 12 
months of life, 2 doses should be given at least 8 weeks 
apart. Hib-MenCY-TT can be co-administered with other 
routine infant vaccinations, including 13-valent 
pneumococcal conjugate vaccine. Hib-MenCY-TT should 
not be co-administered with other Hib-containing vaccines. 
Infants at increased risk who are vaccinated with Hib- 
MenCY-TT do not need to be vaccinated with MenACWY 
until the first booster dose (3 years after completion of the 
Hib-MenCY-TT series), unless another indication is present 
(e.g., travel to countries in which meningococcal disease is 
hyperendemic or epidemic).
• Persons aged 9 months through 55 years. Persons aged 
9 months through 55 years at increased risk for 
meningococcal disease should receive MenACWY. Infants 
aged 9 through 23 months are recommended to receive a
2-dose primary series with a dosing interval of 12  weeks. 
Infants who have been vaccinated with Hib-MenCY-TT 
do not need to receive MenACWY unless they are traveling 
to areas with high endemic rates of meningococcal disease 
and require protection with Serogroups A and W  Persons 
aged 2 through 55 years are recommended to receive a 
single dose or a 2-dose primary series based on the 
indication for vaccination.
• Persons aged >56 years. MPSV4 is the only licensed 
meningococcal vaccine for adults aged >56 years and is 
immunogenic in older adults. For adults who have received 
MenACWY previously, limited data demonstrate a higher 
antibody response after a subsequent dose of MenACWY 
compared with a subsequent dose of M PSV4 . For 
meningococcal vaccine-naïve persons aged >56 years who 
anticipate requiring a single dose of meningococcal vaccine 
(e.g., travelers and persons at risk as a result of a community 
outbreak), MPSV4 is preferred. For persons now aged >56 
years who were vaccinated previously with MenACWY 
and are recommended for revaccination or for whom 
multiple doses are anticipated (e.g., persons with asplenia 
amd microbiologists), MenACWY is preferred.
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TABLE 7. Recommended immunization schedule and intervals for persons at increased risk for meningococcal disease - 
on Immunization Practices (ACIP), United States, 2012*
- Advisory Committee
Age group Subgroup Primary vaccination Booster dose+
2-18 mos with Children who:
high-risk conditions5 • have persistent complement deficiencies
• have functional or anatomic asplenia
• are at risk during a community outbreak 
attributable to a vaccine serogroup
9-23 mos with Children who:
high-risk • have persistent complement deficiencies
conditions' • travel to or are residents of countries where
meningococcal disease is hyperendemic or 
epidemic
• are at risk during a community outbreak 
attributable to a vaccine serogroup
2-55 yrs with Persons who:
high-risk conditions • have persistent complement deficiencies
and not vaccinated • have functional or anatomic asplenia
previously • have HIV, if another indication for
vaccination exists
Persons who:
• are first-year college students aged <21 
years living in residential housing
• travel to or are residents of countries where 
meningococcal disease is hyperendemic or 
epidemic
• are at risk during a community outbreak 
attributable to a vaccine serogroup
• are microbiologists routinely exposed to 
isolates of Neisseria meningitidis
4 doses of Hib-MenCY-TT (MenHibrix), at 
2, 4, 6, and 12-15 months
2 doses of MenACWY-D (Menactra), 
12 weeks apart**
2 doses of MenACWY, 8-12 weeks apartt+
Person remains at increased risk and 
completed the primary dose or series at 
age:
• 2 mos-6 yrs: Should receive additional 
dose of MenACWY 3 yrs after primary 
immunization; boosters should be 
repeated every 5 yrs thereafter
• >7 yrs: Should receive additional dose 
of MenACWY 5 yrs after primary 
immunization; boosters should be 
repeated every 5 yrs thereafter
1 dose of MenACWYt+
Source: Adapted from American Academy of Pediatrics. Meningococcal infections. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red book: 2012 report of 
the Committee on Infectious Diseases. 29th ed. Elk Grove, IL: American Academy of Pediatrics; 2012: 500-9.
* Includes persons who have persistent complement deficiencies (e.g., C5-C9, properdin, factor H, or factor D), and anatomic or functional asplenia; travelers to or residents
of countries in which meningococcal disease is hyperendemic or epidemic; and persons who are part of a community outbreak of a vaccine-preventable serogroup.
t If the person remains at increased risk for meningococcal disease.
§ Infants and children who received Hib-MenCY-TT and are travelling to areas with high endemic rates of meningococcal disease such as the African "meningitis belt” 
are not protected against serogroups A and W-135 and should receive a quadrivalent meningococcal vaccination licensed for children aged >9 months prior to travel.
'  Because of high risk for invasive pneumococcal disease, children with functional or anatomic asplenia should not be immunized with MenACWY-D (Menactra) 
before age 2 years to avoid interference with the immune response to the pneumococcal conjugate vaccine (PCV) series.
** If an infant is receiving the vaccine prior to travel, 2 doses may be administered as early as 8 weeks apart. 
ft If MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.
P e r s o n s  W h o  H a v e  P e r s i s t e n t  C o m p l e m e n t  
C o m p o n e n t  D e f ic ie n c ie s  (C3, C 5 -9 , 
P r o p e r d in ,  F a c to r  D, a n d  F a c to r  H)
• A  2-dose primary series of MenACWY administered 8-12 
weeks apart, is recommended for persons aged 9 months 
through 55 years with persistent deficiencies of the late 
complement component pathway.
• A  4-dose primary series of H ib-M enCY-TT can be 
administered to infants aged 2 through 18 months with 
known persistent deficiencies of the late complement 
component pathway.
• A  booster dose should be administered every 5 years; 
children who receive the primary series before their seventh 
birthday should receive the first booster dose in 3 years 
and subsequent doses every 5 years.
Persons W ho Have A natom ic or Functional 
A splenia
• A  2-dose primary series of MenACWY administered 8-12 
weeks apart is recommended for persons aged 2 through 
55 years with anatomic or functional asplenia.
• A  4-dose primary series ofHib-MenCY-TT is recommended 
for infants aged 2 through 18 months.
• Infants aged 19 through 23 months who have not received 
Hib-MenCY-TT should defer vaccination with MenACWY 
until age 2 years and completion of the PCV-13 series.
• A  booster dose should be administered every 5 years; 
children who receive the primary series before their seventh 
birthday should receive the first booster dose in 3 years 
and subsequent doses every 5 years.
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M icrobiologists W ho Are Exposed Routinely to  
Isolates o f N. m eningitidis
• M icrobiologists routinely exposed to isolates o f 
N .  m e n i n g i t i d i s  are recommended to receive a single dose 
of MenACWY. A  booster dose should be administered 
every 5 years if  exposure is ongoing.
Persons W ho Travel to  or Reside in C ountries in 
Which M eningococcal D isease Is H yperendem ic 
or Epidemic, Particularly if C ontact w ith th e  Local 
Population  Will Be P rolonged
• For international travelers, vaccination is recommended for 
those visiting the parts of sub-Saharan Africa known as the 
“meningitis belt” during the dry season (December-June).
• International travelers should receive a booster dose of 
MenACWY if  the last dose was administered 5 or more 
years previously. Vaccination in the 3 years before the date 
of travel is required by the government of Saudi Arabia 
for all travelers to Mecca during the annual Hajj.
• Children aged 9 through 23 months can receive the second 
dose as early as 8 weeks after the first dose before travel.
• Infants and children who received Hib-MenCY-TT and are 
travelling to areas with high endemic rates of meningococcal 
disease are not protected against serogroups A  and W and 
should receive 1 or 2 doses of a quadrivalent meningococcal 
vaccination licensed for children aged >9 months before 
travel (dependent on age at vaccination and product used 
[see Table 7]).
• Advisories for travelers to other countries are issued by 
CD C when epidemics of meningococcal disease caused 
by vaccine-preventable serogroups are detected. Travelers’ 
health information is available from CD C toll free at 
telephone 1-877-394-8747 (1-877-FY I-TR IP ) or at 
http://ww w.cdc.gov/travel. Further inform ation 
concerning geographic areas for which vaccination is 
recommended can be obtained from international health 
clinics for travelers and state health departments.
Persons w ith H um an Im m unodeficiency  Virus
• H IV  infection is not an indication for routine MenACWY 
vaccination.
• Persons with H IV  infection who are recommended 
routinely to receive vaccine (i.e., persons aged >9 months 
at increased risk for meningococcal disease and all persons 
aged 1 1  through 18 years) should receive a 2-dose primary 
series, administered 8-12  weeks apart, because evidence 
suggests that persons with H IV  do not respond optimally 
to a single dose (3, 4) .
First-Year College S tu d en ts  Living in Residence 
Halls
• First-year college students living in residence halls should receive 
at least 1 dose ofMenACWY before college entry. The preferred 
timing ofthe most recent dose is on or after their 16 th birthday.
• I f  only 1 dose of vaccine was administered before the 16th 
birthday, a booster dose should be administered before 
enrollment.
• Some schools, colleges, and universities have policies requiring 
vaccination against meningococcal disease as a condition of 
enrollment for either incoming first-year students living in 
residence halls or all incoming first-year students. For ease of 
program implementation, persons aged <21 years should have 
documentation ofreceipt ofmeningococcal conjugate vaccine 
not more than 5 years before enrollment.
O utbreaks o f M eningococcal D isease
MenACWY or Hib-MenCY-TT is recommended for use in 
control of outbreaks caused by vaccine-preventable serogroups 
(A, C , Y, and W-135) of N .  m e n i n g i t i d i s  (Appendix B). An 
outbreak is defined by the occurrence of at least three confirmed 
or probable primary cases of meningococcal disease caused by the 
same serogroup in <3 months, with a resulting primary attack 
rate of >10 cases per 100,000 population. For calculation of this 
threshold, population-based rates are used rather than age-specific 
attack rates. MenACWY is preferred ifthe population targeted for 
vaccination includes age groups for which MenACWY is licensed 
(i.e., 9 months through 55 years). Detailed recommendations 
on evaluation and management of suspected outbreaks of 
meningococcal disease are provided (Appendix B).
Children A ged 2 M onths th ro u g h  10 Years Not at 
Increased Risk for M eningococcal D isease
Routine vaccination against meningococcal disease is not 
recommended for children aged 2 months through 10 years. Hib- 
MenCY-TT is licensed as a 4-dose primary series for children aged 
6 weeks through 18 months. Hib-MenCY-TT can be administered 
in any infant for routine vaccination against Hib and will offer 
some protection against serogroups C and Y  meningococcal 
disease; 4 doses of Hib-MenCY-TT fulfill the primary series and 
booster dose Hib immunization recommendations. If  the reason 
for use ofHib-MenCY-TT vaccine is to achieve protection against 
serogroups C and Y, it should be used for all 4 doses of Hib 
vaccine. Infants and children who received Hib-MenCY-TT and 
are travelling to areas with high endemic rates of meningococcal 
disease such as the “meningitis belt” are not protected against 
serogroups A  and W -135 and should receive a quadrivalent 
meningococcal conjugate vaccine licensed for children aged >9 
months before travel.
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MenACWY-D is licensed as a 2-dose primary series for 
children aged 9 through 23 months and as a single dose 
for children ages 2 through 10 years. MenACWY-CRM is 
licensed as a single dose for children aged 2 through 10 years. 
Children who receive Hib-MenCY-TT, MenACWY, or both 
Hib-MenCY-TT and MenACWY before their 10th birthday 
should receive the routinely recommended doses at age 1 1  or 
12  years and at age 16 years.
A d m in i s t r a t io n
MenACWY-D, MenACWY-CRM, and Hib-MenCY-TT 
vaccines are administered intramuscularly, and MPSV4 is 
administered subcutaneously. Individual doses of all vaccines 
are 0.5 mL. In persons aged 2 through 55 years, MenACWY 
and MPSV4 vaccines can be administered concomitantly 
with other vaccines, but at a different anatomic site, if  feasible. 
Because of limited data suggesting immunologic blunting of the 
meningococcal vaccine, MenACWY-D should be administered 
to children aged 2 through 6 years either before, at the same time, 
or more than 6 months after receipt of DTaP IfMenACWY-D is 
administered inadvertently in the 6 months after receipt ofDTaP 
the dose does not need to be repeated. MenACWY-CRM may 
be administered at any time in relation to DTaP administration. 
If  a child is traveling to a high-risk area or is part of a community 
outbreak, waiting to administer MenACWY-D following receipt 
of DTaP is not recommended, even if  there may be blunting. 
There is no evidence of immunologic blunting between Tdap and 
MenACWY when either MenACWY-D or MenACWY-CRM is 
administered following administration ofTdap.
In children aged 2 through 18 months, Hib-MenCY-TT can 
be administered concomitantly with other vaccines, but at a 
different anatomic site, if  feasible. In children aged 9 through 23 
months, MenACWY-D can be administered with other vaccines 
concomitantly in healthy children at different anatomic sites, if  
feasible. Children with asplenia should not receive MenACWY-D 
concomitantly with PCV13; if  MenACWY-D is used in persons 
with asplenia, it should be administered at least 4 weeks after 
completion of all PCV13 doses.
All health-care personnel administering vaccinations should 
be aware of the potential for syncope after vaccination, 
especially among adolescents, and should take appropriate 
measures to prevent potential injuries. If  syncope occurs, the 
vaccine recipient should be observed until symptoms resolve. 
Providers should strongly consider observing patients for 15 
minutes after they are vaccinated ( 97) .
P r e c a u t io n s  a n d  C o n t r a in d ic a t io n s
Vaccination with MenACWY, MPSV4, or Hib-MenCY-TT is 
contraindicated among persons known to have a severe allergic
reaction to any component of the vaccine, including diphtheria 
or tetanus toxoid. ACIP does not consider a history of GBS to be 
a contraindication or precaution for meningococcal vaccination.
Recommended vaccinations can be administered to persons 
with minor acute illness (e.g., diarrhea or mild upper- 
respiratory tract infection with or without low grade fever). 
Vaccination should be deferred for persons with moderate 
or severe acute illness until the person’s condition improves 
( 101) .  Because MenACWY, MPSV4, and Hib-MenCY-TT are 
inactivated vaccines, they can be administered to persons who 
are immunosuppressed as a result of disease or medications; 
however, response to the vaccine might be less than optimal.
V a c c in a t in g  D u r in g  P r e g n a n c y  
a n d  B r e a s t f e e d in g
To date, no randomized, controlled clinical trials have been 
conducted primarily to evaluate use of MPSV4 or MenACWY 
vaccines in pregnant or lactating women. VAERS reports ofexposure 
to MPSV4 during pregnancy have not identified adverse effects 
among either pregnant women or newborns of women vaccinated 
during pregnancy. From VAERS reports available for women found 
to be pregnant at the time of MenACWY-D vaccination, no major 
safety concerns associated with vaccination have been identified in 
the mother or fetus. Pregnancy should not preclude vaccination 
with MenACWY or MPSV4, if  indicated. Women of childbearing 
age who become aware that they were pregnant at the time of 
MenACWY vaccination should contact their health-care provider or 
the vaccine manufacturer so that their experience might be captured 
in the manufacturer’s registry ofvaccination during pregnancy. Any 
adverse event following receipt ofMenACWY, MPSV4 or Hib- 
MenCY-TT vaccine should be reported to VAERS at telephone 
1-800-822-7967 or at http://vaers.hhs.gov/ipdex.
F u t u r e  M e n i n g o c o c c a l  V a c c i n e s ,  
A r e a s  f o r  R e s e a r c h ,  a n d  P u b l i c  
E d u c a t i o n
MenACWY vaccines were licensed on the basis of data 
regarding safety and short-term immunogenicity. However, 
immunogenicity data alone are insufficient to predict vaccine 
effectiveness and herd immunity effect, which depends largely 
on the ability ofvaccine to alter transmission patterns. Multiple 
changes to the recommendations have been made since 2005 
(Box 1); the effect of these changes needs to be monitored over 
time for their effectiveness and impact on disease to be assessed.
Because serogroup B capsular polysaccharide is poorly 
immunogenic in humans, vaccine development for serogroup B 
N .  m e n i n g i t i d i s  has focused on common proteins, including the
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outer membrane vessicles (OMV) of specific epidemic strains. 
Efficacy of OMV vaccines has been demonstrated among older 
children and adults but not among infants and young children, 
in whom rates of disease are highest ( 102— 105) .  In addition, 
the variability in OMV strains causing endemic disease will 
likely limit their usefulness in the United States ( 106, 107) .
Two vaccines developed to prevent serogroup B vaccine 
are in late-stage clinical development in the United States. 
A  multicomponent serogroup B meningococcal vaccine 
(4CMenB), approved for use in Europe by the European 
Medicines Agency in January 2013, was developed by 
sequencing the meningococcal B genome and testing surface 
antigens for their ability to elicit an immunogenic response. 
Three novel antigens identified, factor-H binding protein 
(fHbp), N e i s s e r i a l  adhesion A  (NadA), and N e i s s e r i a  heparin 
binding antigen (NHBA), were combined with OM V from 
the New Zealand epidemic strain N Z98/254 ( 108) .  The 
second vaccine, bivalent recombinant lipoprotein 2086 
vaccine, contains two families of the same protein, fHbp, as 
4CMenB (109). When these vaccines are licensed, vaccines 
to prevent all five serogroups that cause most meningococcal 
disease worldwide will be available for the first time. However, 
extensive research is needed to understand better how to 
conduct optimal implementation of noncapsular based 
meningococcal vaccines.
Although the signs and symptoms of meningococcal 
disease are frequently nonspecific, increasing awareness for 
meningococcal disease can result in earlier medical care- 
seeking behavior and improved clinical outcomes. In addition, 
educating adolescents and their parents about the benefits of 
receiving MenACWY is key to preventing a substantial number 
of cases of meningococcal disease. Finally, educating policy 
makers and the general public about the benefits of receiving 
MenACWY vaccine might improve vaccination coverage rates 
and substantially decrease the burden of meningococcal disease 
in the United States.
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A P P E N D IX  A
A n tim ic r o b ia l  C h e m o p r o p h y la x is
Antimicrobial chemoprophylaxis of close contacts of a patient 
with invasive meningococcal disease is important to prevent 
secondary cases (Table). Close contacts include 1 ) household 
members (1 ), 2) child-care center contacts ( 2,3) ,  and 3) anyone 
directly exposed to the patient’s oral secretions (e.g., through 
kissing, mouth-to-mouth resuscitation, endotracheal intubation, 
or endotracheal tube management) in the 7 days before symptom 
onset. Health-care personnel should receive chemoprophylaxis 
if  they were managing an airway or exposed to respiratory 
secretions of a patient with meningococcal disease. For travelers, 
antimicrobial chemoprophylaxis should be considered for any 
passenger who had direct contact with respiratory secretions 
from an index-patient or for anyone seated directly next to an 
index-patient on a prolonged flight (i.e., one lasting >8 hours) 
(4). The attack rate for household contacts exposed to patients 
who have sporadic meningococcal disease was estimated to 
be four cases/1,000 persons exposed, which is 500-800 times 
greater than the rate for the total population (5). In the United 
Kingdom, the attack rate among health-care personnel exposed 
to patients with meningococcal disease was 25 times higher than 
among the general population (6).
Chemoprophylaxis is not recommended for close contacts 
of patients with evidence of N e i s s e r i a  m e n i n g i t i d i s  only in 
nonsterile sites such as an oropharyngeal swab, endotracheal 
secretions, or conjunctival swab. Reports of secondary 
cases after close contact to persons with 
noninvasive pneumonia or conjunctivitis 
are rare; there is no evidence of substantive 
excess risk (7—9). Furthermore, there is 
no indication to treat persons who are 
asymptomatic nasopharyngeal carriers.
Because the rate of secondary disease for close 
contacts is highest immediately after onset of 
disease in the index patient, antimicrobial 
chemoprophylaxis should be administered 
as soon as possible (ideally <24 hours after 
identification ofthe index patient). Conversely, 
chemoprophylaxis administered >14 days 
after exposure to the index patient is probably 
of limited or no value. Oropharyngeal or 
nasopharyngeal cultures are not helpful in 
determining the need for chemoprophylaxis 
and might delay institution of this preventive 
measure unnecessarily.
Rifampin, ciprofloxacin, and ceftriaxone are 90% -95% effective 
in reducing nasopharyngeal carriage of N .  m e n i n g i t i d i s  and are all 
acceptable antimicrobial agents for chemoprophylaxis ( 10—13) .  
Although sporadic resistance to rifampin and ciprofloxacin 
have been reported worldwide, meningococcal resistance to 
chemoprophylaxis antibiotics remains rare in the United States. 
Clinicians should report suspected chemoprophylaxis failures to 
their public health departments. Systemic antimicrobial therapy 
of meningococcal disease with agents other than ceftriaxone 
or other third-generation cephalosporins might not eradicate 
nasopharyngeal carriage of N .  m e n i n g i t i d i s  reliably. If  other agents 
have been used for treatment, the index patient should receive 
chemoprophylactic antibiotics for eradication of nasopharyngeal 
carriage before being discharged from the hospital (14).
Although azithromycin is not recommended for use as a first-line 
chemoprophylaxis agent, one study has reported that a single 500-mg 
oral dose ofazithromycin was effective in eradicating nasopharyngeal 
carriage ofN .  m e n i n g i t i d i s  (15). Azithromycin, in addition to being 
safe and easy to administer, is also available in a suspension form 
and is approved for use among children. Azithromycin has been 
recommended for prophylaxis in the rare circumstance of sustained 
ciprofloxacin resistance in a local community; however, further 
evaluation is warranted of both the effectiveness of azithromycin in 
eradicating carriage of N .  m e n i n g i t i d i s  and potential for development 
of microbial resistance (15).
TABLE. Recommended chemoprophylaxis regimens for protection against meningococcal 
disease —  Advisory Committee on Immunization Practices (ACIP), United States, 2012
Drug Age group Dosage
Duration and route 
of administration*
Rifampin+ Children aged <1 mo 5 mg/kg every 12 hrs 2 days
Children aged >1 mo 10 mg/kg every 12 hrs 2 days
Adults 600 mg every 12 hrs 2 days
Ciprofloxacin5 Adults 500 mg Single dose
Ceftriaxone Children age <15 yrs 125 mg Single IM dose
Ceftriaxone Adults 250 mg Single IM dose
Abbreviation: IM = intramuscular.
* Oral administration unless indicated otherwise.
f Rifampin is not recommended for pregnant women because the drug is teratogenic in laboratory animals. 
Because the reliability of oral contraceptives might be affected by rifampin therapy, consideration should 
be given to using alternative contraceptive measures while rifampin is being administered.
§ Ciprofloxacin is not generally recommended for persons aged <18 years or for pregnant and lactating 
women because the drug causes cartilage damage for immature laboratory animals. However, 
ciprofloxacin may be used for chemoprophylaxis of children when no acceptable alternative therapy is 
available. A recent review identified no reports of irreversible cartilage toxicity or age-associated adverse 
events in children and adolescents (Source: Burstein GR, Berman SM, Blumer JL, Moran JS. Ciprofloxacin 
for the treatment of uncomplicated gonorrhea infection in adolescents: does the benefit outweigh the 
risk? Clin Infect Dis 2002;35:S191-9).
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A P P E N D IX  B
E v a lu a t io n  a n d  M a n a g e m e n t  o f  S u s p e c t e d  O u tb r e a k s  o f  M e n in g o c o c c a l  D is e a s e
As routine vaccination coverage among adolescents with 
MenACWY increases, the number of serogroup C and Y  has 
declined (CDC, unpublished data, 2012). However, outbreaks 
might occur in age groups that are not routinely recommended 
to be vaccinated with MenACWY and deaths caused by 
meningococcal outbreaks can result in high levels of anxiety in a 
community (1). Mass vaccination might play a role protecting the 
population at risk during an outbreak. The decision to implement 
a mass vaccination campaign to prevent meningococcal disease 
depends on whether the occurrence of more than one case 
represents an outbreak or an unusual clustering of endemic 
disease. Because the number of cases in outbreaks is usually not 
substantial, this determination often requires evaluation and 
analysis of the patterns of disease occurrence. Mass vaccination 
campaigns are expensive, require a massive public health effort, 
and can create unwarranted concern among the public. However, 
mass vaccination campaigns might offer an opportunity to increase 
coverage in otherwise hard-to-reach populations (e.g., adolescents 
who have dropped out of school).
P o p u la t io n  a t  R isk: O r g a n iz a t io n -  a n d  
C o m m u n i ty - B a s e d  O u tb r e a k s
In addition to close contacts, persons considered to be at 
increased risk for meningococcal disease compared with historic 
rates of disease in the same population in the general U.S. 
population are classified as being at risk. The population at 
risk is used as the denominator in calculations of the disease 
attack rate. The population at risk is usually defined on the 
basis of organizational affiliation or community of residence. 
In organization-based outbreaks, cases are linked by a common 
affiliation other than a shared, geographically delineated 
community; the population at risk is thus usually the group of 
persons who best represent that affiliation. For example, if  the 
only association between patients is attending the same school or 
university, the population at risk is all persons attending the school 
or university. In community-based outbreaks, patients have no 
common affiliation other than a shared, geographically defined 
community. The population at risk can be defined as the smallest 
geographically contiguous population that includes all (or nearly 
all) patients. This population is usually a neighborhood, town, 
city, or county whose size is obtained from census data.
Distinguishing whether an outbreak should be classified 
as organization- or community-based is complicated by 
the fact that, in certain instances, these types of outbreaks 
occur simultaneously. Calculation of attack rates for
organization-based outbreaks is most useful for large 
organizations (e.g., universities). However, in the majority 
of organization-based outbreaks with three or even two cases 
of disease, the rate will be >10 cases/100,000 population. In 
such situations, public health officials also might consider 
vaccination after only two primary cases are identified.
A tta c k  R a te  a n d  D e c is io n  t o  V a c c in a te
For a primary attack rate to be calculated, all confirmed cases 
(Box) of the same serogroup should be summed; secondary 
cases should be excluded and each set of coprimary cases 
counted as one case. Because attack rates are calculated both to 
characterize the risk for disease among the general population 
and to determine whether overall rates have increased, related 
cases (secondary and coprimary) should not be included.
If  three or more cases have occurred in either an organization- or 
a community-based outbreak during <3 months (starting at the 
time ofthe first confirmed or probable case), a primary attack rate 
should be calculated. Rate calculations should not be annualized. 
The following formula is used to calculate attack rates:
Attack rate per 100,000 = [(number of primary confirmed 
or probable cases during a 3-month period) / (number of 
population at risk)] x 100 ,000.
Vaccination of the population at risk should be considered if the 
attack rate is >10 cases/100,000 persons. Public health personnel 
should consider the following factors: 1 ) completeness of case 
reporting and number of possible cases of meningococcal disease 
for which bacteriologic confirmation or serogroup data are not 
available; 2) occurrence ofadditional cases ofmeningococcal disease 
after recognition of a suspected outbreak (e.g., if the outbreak 
occurred 2 months previously and if  no additional cases have 
occurred, in which case vaccination might be unlikely to prevent 
additional cases of meningococcal disease); and 3) logistic and 
financial considerations. Because available vaccines are not effective 
against N e i s s e r i a  m e n i n g i t i d i s  serogroup B, vaccination should not 
be considered during serogroup B outbreaks.
V a c c in a t io n  G r o u p
Those persons designated to be administered vaccine during 
a vaccination campaign comprise a vaccination group. The 
vaccination group usually includes either the whole or a subset of 
the population of risk. Because meningococcal disease outbreak 
cases occur predominantly among persons aged <30 years (2), the 
vaccination group usually is that portion of the population at risk 
aged <30 years.
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In the majority of organization-based outbreaks, the 
vaccination group includes the whole population at risk. In 
certain organization-based outbreaks, a vaccination group 
larger than the population at risk might be designated. For 
example, in a high school in which all outbreak-associated 
cases occurred among students, authorities might decide to 
offer vaccine to staff. In community-based outbreaks, the 
vaccination group usually can be defined as a subset of the 
population at risk (e.g., persons aged <30 years). In rare 
situations (e.g., in a town with a limited population) in which 
multiple cases have occurred among adults aged >29 years, the 
entire population might be considered for vaccination. For 
more substantial populations, this decision would be costly 
in terms of finances and human resources, and restricting the 
vaccination group to the persons in age groups with the highest 
attack rates might be more appropriate. Age-specific attack 
rates can be calculated by using the formula previously provided 
and by restricting the numerator and denominator to persons 
within specific age groups (e.g., persons aged <30 years).
G e n o ty p in g  o f  N . m e n in g i t id i s  I s o la te s
Genotyping of N .  m e n i n g i t i d i s  isolates by using such methods 
as pulsed-field gel electrophoresis or multilocus sequence analysis 
(M LST) might provide useful information for determining 
whether a group of cases represents an outbreak (3). Outbreaks 
of meningococcal disease usually are caused by closely related 
strains. Genotyping data can allow identification of an outbreak 
strain and help to better define the extent of the outbreak. If  
strains from a group of patients are unrelated by genotyping, the 
group of cases most likely does not represent an outbreak. Because 
molecular subtyping testing might not be readily available or 
accessible, initiation of outbreak-control efforts should not be 
delayed until genotyping results are available.
O th e r  C o n tro l  M e a s u r e s
Mass chemoprophylaxis (i.e., administration of antibiotics to 
substantial populations) is not recommended to control large 
outbreaks of disease. Disadvantages of mass chemoprophylaxis 
include cost of the drug and administration, difficulty of 
ensuring simultaneous administration of drugs to substantial 
populations, drug side effects, and emergence of resistant 
organisms. In addition, multiple sources and prolonged risk 
for exposure make this approach impractical and unlikely to 
succeed. In the majority of outbreak settings, these disadvantages 
outweigh the possible benefit in disease prevention. However, 
in outbreaks involving limited populations (e.g., an outbreak 
in a single school), administration of chemoprophylaxis might 
be considered (4), especially in serogroup B outbreaks, for 
which available vaccines are not effective (5). When making 
a decision about initiating mass chemoprophylaxis in these 
settings, public health officials should consider not only the 
potential for prevention of new cases but also the logistics, 
cost, and potential for developing antimicrobial resistance 
( 6, 7) .  I f  mass chemoprophylaxis is undertaken, it should be 
administered to all targeted persons at the same time. In the 
United States, measures that have not been recommended for 
control of meningococcal disease outbreaks include restricting 
travel to areas with an outbreak, closing schools or universities, 
or canceling sporting or social events.
Educating communities, physicians, and other health-care 
personnel about meningococcal disease to promote an early case 
recognition and early care-seeking behaviors is an important 
part of managing suspected meningococcal disease outbreaks. 
Education efforts should be initiated as soon as an outbreak 
of meningococcal disease is suspected (7). Information about 
the signs and symptoms of meningococcal disease is available 
at http://www.cdc.gov/meningococcal/about/symptoms.html.
• Confirmed case. A confirmed case of meningococcal 
disease is one that is defined by isolation of 
Neisseria meningitidis from a normally sterile site (e.g., 
blood or cerebrospinal fluid) from a person with clinically 
compatible illness.
• Probable case. A probable case of meningococcal disease is 
one that is defined by detection of polysaccharide antigen or 
nucleic acid in cerebrospinal fluid (e.g., by latex 
agglutination, polymerase chain reaction, or 
immunohistochemistry) or the presence of clinical purpura 
fulminans in the absence of diagnostic culture from a person 
with clinically compatible illness.
• Primary case. A primary case of meningococcal disease is 
one that occurs in the absence of previous known close 
contact with another patient.
• Secondary case. A secondary case of meningococcal disease 
is one that occurs among close contacts of a primary 
patient >24 hours after onset of illness in the primary 
patient.
• Coprimary cases. Coprimary cases are two or more cases 
that occur among a group of close contacts with onset of 
illness separated by <24 hours.
• Close contacts. Close contacts of a patient who has 
meningococcal disease include 1) household members; 2) 
child-care center contacts; and 3) persons directly exposed to 
the patient’s oral secretions (e.g., by kissing, mouth-to- 
mouth resuscitation, endotracheal intubation, or 
endotracheal tube management).
• Source: Council of State and Territorial Epidemiologists position statement 
(available at http://www.cste.org/ps2009/09-id-42.pdf).
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